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Resumo  
 
Introdução: O cancro do esófago, atualmente considerado uma doença agressiva e com 
taxas de sobrevivência particularmente baixas, estima-se estar na sétima posição de 
incidência, a nível mundial, sendo a sexta causa de morte por cancro. Os principais subtipos 
histológicos subdividem-se em carcinoma de células escamosas e adenocarcinoma do 
esófago. Apesar dos avanços promissores nas aplicações terapêuticas neste tipo de tumores, 
nomeadamente na radioterapia, o prognóstico para estes doentes continua desfavorável. Além 
disso, a hipóxia, característica predominante em muitos tumores sólidos, representa uma das 
principais formas de resistência à radioterapia. Assim, a nível molecular, o microambiente 
hipóxico caracteriza-se pela ativação e indução de fatores de transcrição (HIFs) que medeiam 
a transcrição de genes reguladores de várias vias de sinalização nas células. A possível 
interação entre estes fatores e marcadores epigenéticos não é ainda totalmente 
compreendida, no entanto, já foi várias vezes apontada com potencial terapêutico em alguns 
modelos tumorais. Portanto, o principal objetivo deste estudo é compreender a interação entre 
a hipóxia e a modelação epigenética, bem como a sua implicação que isso tem na resposta à 
radioterapia, tentando realçar a importância de marcadores epigenéticos como marcadores 
preditivos de terapia no cancro do esófago.  
 
Material e métodos: Linhas celulares de carcinoma de células escamosas do esófago foram 
usadas para avaliar a resposta à radioterapia através da determinação das curvas de 
sobrevivência com o ensaio da formação de colónias, irradiando numa escala de 0 a 8 Gy nas 
condições de hipoxia e CoCl2, comparando com uma situação de normoxia. A expressão de 
marcadores epigenéticos e do HIF-1α foram avaliadas ao nível do transcrito e da proteína, 
através de qRT-PCR, WB e IF em linhas celulares e através de IHC em tecidos parafinados. 
Por fim, vários parâmetros de agressividade foram acedidos através de ensaios funcionais, 
antes e após o tratamento com um inibidor das desmetilases de histonas (IOX1), avaliando, 
novamente, a resposta à radioterapia.  
 
Resultados e Discussão: Os tecidos tumorais de esófago apresentaram maior expressão de 
enzimas desmetilantes de histonas comparativamente aos tecidos normais. Em ensaios in 
vitro observou-se o aumento da expressão do HIF-1α em condições de hipóxia comparando 
com níveis basais de oxigénio. Além disso, verificou-se uma correlação significativa da 
  
 
 xxviii 
expressão do HIF-1α com o aumento do transcrito das enzimas desmetilantes de histonas, 
Jumonji C domínio, nomeadamente, KDM3A, KDM6B e KDM4C, tanto em tumores primários 
como nas linhas celulares. Estes resultados estão de acordo com a diminuição da proteína 
das respetivas marcas de histonas, incluindo, H3K9me3 e H3K27me3. A inibição da atividade 
destas enzimas associou-se significativamente com a atenuação das características de 
agressividade celular previamente avaliados, tal como, aumento nos danos do DNA e na 
percentagem de apoptose, bem como uma diminuição da capacidade migratória. Assim, de 
acordo com estas alterações este tratamento proporciona o aumento da radiossensibilidade 
celular no carcinoma de células escamosas do esófago, com potencialidades terapêuticas.   
 
Conclusão: Os nossos resultados sugerem, que as enzimas desmetilantes de histonas 
estudadas podem constituir biomarcadores preditivos de resposta à radioterapia, sendo 
potencias candidatos para terapias dirigidas no cancro do esófago.   
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Abstract 
 
Introduction: Esophageal cancer (EC), comprising mostly two major histological subtypes - 
squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) - is estimated to be the seventh 
most common cancer and the sixth leading cause of death worldwide. Despite the advances in 
radiotherapy, EC prognosis remains poor. Hypoxic foci in solid tumors are known to endure 
resistance to radiotherapy (RT). At molecular level, hypoxic microenvironment is characterized 
by increased transcription and activation of hypoxia inducible factors’ (HIFs). This was 
suggested to associate with aberrant post-transcriptional modifications and chromatin 
remodelers’ deregulation, leading to inappropriate gene activation or repression. However, the 
interplay between hypoxia and epigenetics is not fully understood. Hence, our aim is to tackle 
the association between epigenetic factors, hypoxia and RT. Importantly, we intend to 
investigate whether those epigenetic changes may be used as predictive markers for EC 
response to radiotherapy under hypoxia conditions. 
 
Materials and Methods: ESCC cell lines were irradiated with RT dosages ranging from 0 to 
8Gy, in presence of 50uM CoCl2/hypoxia stabilization and the effect on cell survival was 
assessed through colony formation assay. The expression of different epigenetic markers and 
hypoxia factor, HIF-1α, were evaluated at transcriptional and protein level in ESCC cell lines 
through qRT-PCR, Western blot and immunofluorescence assays and in paraffin tissues 
through immunohistochemistry. Next several functional assays were performed after drug 
treatment with specific histone lysine demethylase (KDM) inhibitor (IOX1) coupled with RT 
response evaluation. 
 
Results and Discussion: Increased HIF-1α expression was observed in hypoxic cells 
compared to basal conditions. Moreover, significantly increase of KDMs transcriptional levels 
namely KDM3A, KDM4C and KDM6B, were depicted for tissue samples and for all studied cell 
lines, paralleled to decreased H3K9me3 and H3K27me3 protein levels. KDMs activity 
inhibition, leads to a significant alteration in aggressiveness parameters, such as increased 
DNA damage and apoptosis levels and decreased migration capacity after ionizing radiation 
(IR) exposure. In agreement, the radiosensitivity of IOX1 treated cells also increased, being an 
attractive target therapy in hypoxic ESCC patients. 
 
  
 
 xxx 
Conclusions: Our results suggest that the studied KDMs may be predictive biomarkers of 
response to RT, suggesting them as novel candidates for target therapies in EC. 
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1.1 Epidemiology 
Esophageal cancer (EC), including the two major subtypes, adenocarcinoma and 
squamous cell carcinoma, is currently, according to estimate statistics for 2018, the seventh 
leading cause of cancer worldwide and the sixth leading cause of death. Data stratified by sex, 
show, in general, that males have a higher incidence and mortality rates than females, about 
2-fold to 3-fold above [1]. Incidence rates changes by region, mainly due to the prevalence of 
different risk factors among populations. Therefore, regarding the global distribution of this 
neoplasm, there is a clear prevalence in developing countries, especially in Asian regions. 
According to epidemiological studies, the results indicate a general prevalence of esophageal 
squamous cell carcinoma (ESCC) over esophageal adenocarcinoma (EAC) in most countries 
[2]. Like this, EAC has a predominantly high pattern in developed regions including northern 
and Western Europe, northern America and Oceania, with an evident increase in last decades. 
On the other hand,  ESCC has more pronounced distribution, generally, in regions of the East, 
South-east and Central Asia, sub-Saharan Africa and Latin America [2]. 
 
1.2 Etiologic factors 
EC is a public health problem, due to increased incidence in some countries and usually 
has a bad prognosis [3]. Therefore, regarding the main etiological causes for disease, tobacco 
is the major contributor for carcinogenic process in the esophagus. Studies show a strong 
positive dose-response association for smoking and risk of EC development, mainly in ESCC 
[4, 5]. The two major histological types of EC, present a substantial difference in the etiological 
factors responsible for the disease (Figure. 1).  
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As a result of modern living habits in developed countries, there is an increase in 
obesity, which is also risk factor in adenocarcinoma. Thus, some studies point to a possible 
association between this factor and the risk of EAC development, with an increased risk about 
1.5 to 3.0 fold (Supplementary Table. 1, Appendix. I) [6-13], particularly central adiposity 
which is a consequence of severe inflammations in the intestinal and esophageal tract [14]. In 
recent decades, some results have shown a statistically significant positive relationship 
between several events, such as obesity association with possible gastroesophageal reflux 
(GERD) [15], as a probable cause of Barrett’s Esophagus (BE) and as a consequence 
increased risk of EAC development [6, 11]. Overweight or body fat can be measured and 
compared through body mass index (BMI). For a better comparison of the risk, this index is 
grouped by categories, and the highest risk groups are usually characterized with  BMI greater 
than 30 Kg/m2 (Supplementary Table. 1, Appendix I).   
The consequent increased incidence of EAC in more developed areas, such as United 
States in the North of America and western countries of Europe, is due to certain risk factors 
prevalence in these regions [16]. The changes in life habits and in daily diet had a potential 
influence in strong increased appearance of this type of disease in the last decades [17]. 
Consequently, GERD is a frequent event in western Countries, with a consecutive increased 
incidence in recent years, being in 2005 the prevalence of this type of disorder around 10-20% 
Figure. 1 Main risk factors for both histological subtypes of esophageal cancer: Esophageal squamous cell 
carcinoma and esophageal adenocarcinoma. Abbreviations: BE, Barrett’s esophagus; EAC, esophageal 
adenocarcinoma; ESCC, esophageal squamous cell carcinoma; GERD, Gastroesophageal reflux disease. 
(Macedo-Silva. C, unpublished) 
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in the main regions previously mentioned [18]. Patients with this disorder have a high 
predisposition to develop BE and consequently EAC. The main symptoms of this chronic 
inflammation, caused by reflux of stomach fluids, are heartburn and regurgitation, which may 
be more or less pronounced and frequent, proportionally to correlated risk [16]. 
A chronic GERD process, with erosive characteristics, it may lead to development of 
metaplastic stage in esophageal cells. BE is then the result of prolonged exposure to stomach 
acid.Thus, metaplasia occurs in the lower portion of the esophagus, and consists, essentially, 
in replacing squamous epithellium with intestinal epithellium [19]. This metaplastic event is 
strongly associated with the EAC appearance, promoting carcinogenesis and is then 
considered a precursor lesion [20-22] (Supplementary Table. 2, Appendix. I). Statistical data, 
point to 2-fold increased risk for any symptom of GERD disease in develop EAC, with higher 
risk groups the individuals who demonstrate symptoms daily or even more than once a day, 
having a risk about 5 times higher than those who do not have any symptoms [16, 23] 
(Supplementary Table. 3, Appendix. I). Other authors have categorized the symptoms 
according to the period of the day that they occur and have shown that individuals who have 
these symptoms at night present a risk of developing cancer higher than the other ones, with 
an odds ratio (OR) of 10.8 compared to an OR of 7.7, respectively [16]. 
In addition, tobacco is also considered, through epidemiological studies, a risk factor for 
EAC, increasing by about 1.6-2.8-fold the risk, when comparing current smokers to non-
smokers [16, 23-25] (Supplementary Table. 4, Appendix I). Therefore, these main risk factors 
referenced in the literature increase a predisposition to develop EAC, explaining, then, the 
significant high prevalence in certain geographic regions, according to particularly life habits. 
Also in relation to EAC, as opposed to the ESCC type, alcohol consumption is not 
significantly associated with EAC development [25]. However, other authors have shown an 
inverse causal association, and thus, alcohol consumption is potentially beneficial in preventing 
the development of adenocarcinoma, with an average per week of 16-70 grams of ethanol [16, 
25, 26] (Supplementary Table. 5, Appendix I).  
Regarding the other histological subtype of EC - ESCC - the main known risk factors 
are tobacco, heavy alcohol consumption and in some cases, an inadequate diet [23]. Several 
studies indicate that the main etiological factor for this type of cancer is smoking. 
Epidemiological data demonstrate an increased risk a 3.0-9.0-fold higher for current smokers 
than for non-smokers [16, 23, 27-29] (Supplementary Table. 4, Appendix I). 
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Moreover, the second factor strongly pointed out as a possible cause of ESCC is alcohol 
consumption. The exposure to this substance shows a strongly causal association with ESCC. 
In this context, the risk varies according to different epidemiological studies, taking into account 
the parameters evaluated by each study. Therefore analyzing risk assessment for alcohol 
consumption, intensive consumers (> 17 drinks/week) present a risk 3.3-fold higher when 
compared to passive consumers (≤ 17 drinks/week) [28], whereas an extreme consumption of 
> 30 drinks / week represents an increased risk of 9.4-fold in relation to non-consumers [16, 
23, 27-29] (Supplementary Table. 5, Appendix I). These two previously mentioned habits 
have a synergistic effect when used simultaneously. Statistical results have shown a positive 
dose-response relationship for both tobacco and alcohol consumption relative to the potential 
carcinogen for develop ESCC with a partial population attributable fraction (PAF) of 58.2 with 
an 95% confidence interval (CI) of [41.9 ; 66.7] [28]. The high prevalence of this histological 
variant in Asian regions, for example in China, where the incidence trend continues to increase, 
is mainly related to the life habits, including smoking, alcohol consumption, culture, 
environment, socioeconomic status and life quality [30, 31].  
In addition to these two factors, we have food uptake, particularly, the low consumption 
of fruits and vegetables, as possible cause of ESCC in less developed Asian regions, where 
this type of cancer is most common and there is a poor intake of this type of aliments [32]. 
Epidemiological studies indicated a significant inverse association between fruit and vegetable 
consumption and risk of ESCC development. These results may be limited as it is not possible 
to obtain an accurate count of vitamin or food intake [29, 33, 34] (Supplementary Table. 6, 
Appendix I). Additionally, some events mentioned in literature may contribute to an increased 
risk of ESCC development, being patients classified as high risk according to: head and neck 
cancer history, endoscopic resection, presence of Achalasia (disorder characterized by a 
change in the structure of the esophageal tract), Tylosis (genetic predispositions that makes 
the patient more susceptible than the general population to develop EC) and also the accidental 
caustic ingestion in some children that has been reported as strongly detrimental in increasing 
risk [35]. 
1.3 Diagnosis & Staging 
Despite the curative potential of surgical procedure, most patients with EC, at the time 
of diagnosis, have already developed a more advanced stage of disease [36]. In these patients, 
commonly, resort to neoadjuvant therapies. In order to have a correct patient diagnosis and an 
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adequate therapeutic decision, it is necessary to know exactly the tumor stage, at both clinical 
and pathological level. 
Considering the anatomical structure, diagnosis is based on three portions of the 
esophagus: upper, middle and lower (Figure. 2). The two most common histological subtypes, 
EAC and ESCC, tend to appear mostly in anatomically distinct regions. Thus, EAC is usually 
diagnosed in the uppermost esophagus, often with identification of intestinal cell types, since 
one of the most recurrent forms of diagnosis is through BE. The other subtype – ESCC - 
appears frequently, in the middle and upper portions [37]. 
 
Staging in esophageal cavity is done, as in most tumors, through the International 
staging system, TNM, taking into account several parameters, such as structure and size of 
primary tumor (T), presence or absence of malignant nodules (N) and presence or absence of 
distant metastases (M) Figure. 3 [37, 38]. Additionally, as represented on Figure. 3, EC 
spreads, in more advanced disease stage, often to the brain, liver, bones, lungs and adrenal 
glands, with the liver being the most frequent site [37, 39]. Staging groups of EC and gastro-
esophageal junction (GEJ) tumors are represented on Table.1 according to the European 
Society for Medical Oncology (ESMO) guidelines [40]. 
The diagnosis made by the pathologist, pTNM, is based on microscopic analysis of 
histological specimens, obtaining accurate results that will supplement the information provided 
by the clinical diagnosis, cTNM, which is based essentially on the results obtained through 
imaging techniques, such as computed tomography (CT), endoscopic ultrasound (EUS) and 
CT coupled with Positron Emission Tomography (PET-CT) [37, 41]. 
 
 
Figure. 2 Anatomic division of esophagus. (Macedo-Silva. C, unpublished) 
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Figure. 3 Staging in esophageal cancer based on international system TNM. Tis, Tumor in Situ; T1, Tumor 
cells infiltrate the submucosa or lamina propria; T2, Tumor cells infiltrate muscularis propria; T3, tumor cells infiltrate 
adventitia; T4, Tumor cells infiltrate adjacent structures like aorta; N, regional lymph Nodes; M, metastasis (M1a, 
presence of metastatic cells in cervical lymph nodes; M1b, presence of metastatic cells in other distant structures). 
(Macedo-Silva. C unpublished).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tis – Tumor in Situ; T1-T4 – Tumor invade from lamina propria or submucosa to sub adjacent structures; T4a – 
tumor invades pleura, pericardium, diaphragm or adjacent peritoneum; T4b – Tumor invades other adjacent 
structures (aorta, vertebral body or trachea); N representing presence of metastatic lymph nodes, being that N1 
means with 1-2, N2, 3-6 and N3, 7 or more; M representing presence (M1) or absence (M0) of distant metastasis.  
 
Stage Grouping T, Primary tumor 
size
N , lymph nodes M, distant 
metastasis
0 Tis N0 M0
IA T1 N0 M0
IB T2 N0 M0
IIA T3 N0 M0
IIB T1,T2 N1 M0
IIIA T4a N0 M0
T3 N1 M0
T1,T2 N2 M0
IIIB T3 N2 M0
IIIC T4a N1,N2 M0
T4b Any N M0
Any T N3 M0
IV Any T Any M M1
Table. 1 Stage Grouping of EC and GEJ according ESMO Guidelines.  
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1.4 Therapeutic approaches 
In the past few years, therapeutic advances had an increment in EC survival [3]. 
However, according to the literature, the 5-year survival rates for patients remains only 15-20% 
[42]. Most patients at diagnosis, are already in advanced stages and with no indication for 
surgery, namely, esophagectomy, a gold-standard treatment for early stages. However, even 
when surgery can be performed it leads to several comorbidities with a patient’s long-term poor 
quality of life [36, 43]. Currently, just for loco regional tumors, surgery remains the first 
therapeutic option with a 5-year survival rate up to 40% [44].In early stage tumor, with only 
superficial lesions, patients still have the possibility of resorting to endoscopic treatment to 
imaging methods, a less invasive therapy [45].  
Unfortunately, most tumors are frequently diagnosed in advanced stages. Therapeutic 
options for advanced esophageal tumors are neoadjuvant therapies, including chemo and 
radiotherapy. Recently, the concept of trimodality therapy emerged, which is applied to patients 
with locally advanced disease and consists of a pre-treatment with concomitant 
chemoradiotherapy (CRT) followed by surgical resection of the remaining tumor mass, with an 
increase in survival rate [43, 44].  
 
1.5 Radioresistant properties and radiobiology in esophageal cancer  
Radiotherapy (RT), often as first-line treatment of EC, plays an important role on 
improved survival rates of these patients. CRT is considered the gold standard treatment for 
locally advanced EC, namely for unresectable tumors [46]. CTR is often applied as a 
preoperative treatment, increasing the survival benefit for these patients [47]. The dose 
recommended by the guidelines in Europe is 50.4 Gy as total dose of fractionated treatment, 
namely 28 fractions of about 2 Gy, in one fraction per day [48, 49]. Although the advances in 
therapeutic accuracy and precision techniques with tridimensional treatments, such as 
intensity-modulated RT (IMRT) or volumetric-modulated arc therapy (VMAT), the 
heterogeneous tumor mass still can present several forms of therapy resistance and in long 
term, recurrences or even metastasis may occur [49].  
The outcome of standard clinical radiation treatment is determined by the R´s of 
radiobiology, including repair, redistribution, repopulation, reoxygenation and radiosensitivity 
(Figure. 4).  
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Repair of sublethal DNA damage is one of the R’s of radiobiology, which is explained 
by the fact that normal cell are more effective than tumor cells in this process as observed from 
cell recovery in the 2 hour period after exposure to ionizing radiation (IR). Radiation randomly 
interacts with molecules in the cell but DNA is the main target molecule for the biological effects 
of radiation, including cell killing, carcinogenesis and mutation. In RT, radiation damage is 
primarily manifested by the loss of reproductive capacity. Radiation causes a wide range of 
lesions in DNA such as single (SSB) and double-strand breaks (DSB) in the sugar-phosphate 
backbone of the DNA molecule. SSB can be readily repaired using the undamaged chromatid 
as a template. The most deleterious lesion induced by ionizing radiation is DSB, a break in both 
strands of 10 base pairs or less. There are several mechanisms to repair DSBs, which indicate 
the importance and difficulty of repairing this type of DNA injury. The most important are non-
homologous end joining (NHEJ) and homologous recombination (HR). Homologous 
recombination provides greater repair accuracy than NHEJ, the major pathway to repair DSB 
throughout all the phases of the cell cycle [50].  
Figure. 4 5R’s of radiobiology. Schematic representation of 5R’s of radiobiology, such as repair, repopulation, 
redistribution, reoxygenation and radiosensitivity. IR, ionizing radiation.  
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Redistribution applies when radiotherapy is given to a heterogeneous cell population 
and cells may be in different phases of the cell cycle. Cells in S phase are more radioresistant 
and cells in late G2 and M phases are more sensitive. A small dose of radiation will destroy the 
more sensitive cells, and a resistant cell population that is now synchronized survives. After 
fractionated RT treatment, the resistant surviving cells will continue throughout the cell cycle 
and when a new dose is delivered some of these cells have moved from a resistant to a more 
sensitive stage and will then be killed more easily [51]. 
Sometimes after irradiation an increase in cell division is seen in normal and malignant 
cells. Repopulation, another R of radiobiology, occurs at different rates depending on the 
tissues and represents cell proliferation, acting by compensate the cell population that was 
killed. This homeostatic response to cell loss occurs in situations other than irradiation and is 
related to specific cell-cycle time. As a result of radiotherapy, cell death occurs after irradiated 
cells attempt mitosis and thus highly proliferative tissues (and tumors) show damage much 
faster than slowly proliferative tissues [52]. 
The level of oxygenation in a tumor is a major determinant of RT effectiveness. Thus 
reoxygenation constitute another R of radiobiology. As known, tumor cell microenvironment 
presents areas with decreased pH, lack of nutrients and hypoxia. Oxygen concentration (pO2) 
varies between 10 and 80 mm Hg in normal tissues but in tumors these values can be lower 
than 5 mm Hg in some areas. This anomaly is due to the development of abnormal vasculature 
during tumor angiogenesis. A significant proportion of tumor cells is hypoxic, showing great 
heterogeneity that is not correlated with standard prognostic factors such as size, stage and 
histological type [53]. Hypoxia may have a crucial role in treatment outcome and may also 
influence metastatic capacity of tumor cells resulting from genetic and epigenetic changes such 
as those involving blood oxygen transport or inducing vascularization. As a result of prolonged 
exposure to hypoxia, cells can acquire resistance to apoptosis suggesting that hypoxia can 
favor tumor progression through clonal selection of cells with more aggressive phenotypes [52]. 
After an initial dose of RT, the more sensitive oxygenated cells are killed. During reoxygenation, 
surviving tumor hypoxic cells can increase their oxygen supply thus increasing their sensitivity. 
Biological efficacy of IR relies on oxygen interacting with cells and making DNA lesions 
permanent [53] 
Dividing total dose in several fractions saves normal tissue due to sublethal damage 
repair and cell repopulation occurring between treatment fractions. At the same time 
fractionation allows greater damage to the tumor as a result of hypoxic cells reoxygenation as 
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well as redistribution of cells into more radiosensitive stages of the cell cycle. Therefore DNA 
repair and cell repopulation mechanisms induce normal tissues to become more resistant to a 
following dose of radiation. The other R’s, namely redistribution and reoxygenation have the 
opposite effect increasing radiosensitivity of tumor cells. The R’s represent the factors that 
modify tissue response to fractionated radiotherapy - overall radiosensitivity of a specific tumor 
depends upon a 5th R – Radiosensitivity - that translates the outcome of all other R’s and 
represents individual sensitivity to radiation. These five fundamental factors represent the 
biological basis of radiotherapy [54]. 
Since the main aim of RT is to induce double-stranded DNA damage and consequently 
cell death, it is necessary to understand the repair mechanisms at the molecular level 
underlying radioresistance. Several studies have proposed molecular targets to enhance 
radiotherapeutic efficacy, however, the modulation of tumor microenvironment and its own 
heterogeneity are involved in radioresistant processes [48]. Acquired aggressive phenotype or 
cell cycle deregulated markers or even hypoxic regions are the main known forms of cell 
escape to IR for several tumor models [55, 56].  
 
1.6 Brief overview of hypoxia and tumor aggressiveness  
It has been described on the literature, that most solid tumors present hypoxic regions 
characterized by low oxygen levels. This particular phenotype provides several molecular 
changes in the tumor, which are responsible for acquiring aggressive properties through a set 
of genetic and epigenetic modulations associated with poor prognostic features [57, 58].  
Primarily, the adaptive hypoxic event is mainly mediated by a family of transcription 
factors – hypoxia-inducible factors (HIF) with an oxygen-label subunit α and a constitutively 
expressed β stable subunit, involved in increased cell proliferation, inflammation, angiogenesis, 
glycolytic metabolism and tumor aggressiveness. These family allows to driving oncogene 
transcription through hypoxic responsive elements (HRE) [59]. At normal conditions, the tumor 
suppressor protein Von Hippel Lindau (pVHL) together with prolyl-hydroxylases (PHDs) oxygen 
sensors proteins, leading to HIFs degradation [60]. Contrarily, at low oxygen levels, as occurs 
in tumor hypoxic regions, HIF-1α transcription is chronically stabilized which leads to 
downstream signaling pathways modulation, promoting tumor growth [60, 61].  
Moreover, in some experimental studies, a way to mimic a hypoxic condition for 
metabolic studies is through certain metals which induce HIF-1α stabilization, such as cobalt 
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chloride (CoCl2), desferrioxamine (C25H48N6O8) and nickel chloride (NiCl2). These chemicals 
act through the PHDs activity inactivation on the iron binding site, consequently preventing 
interaction with pVHL and thus stabilize HIF-1α protein [62].  
The increased aggressiveness of hypoxic environment also influences the response to 
therapy, particularly, RT [63]. It is known that reactive oxygen species (ROS) interact with DNA 
damage, the main mechanism action of IR. Thus, chronic hypoxic regions of the tumor 
decrease radiosensitivity and consequently therapy efficacy is reduced [64, 65]. Since hypoxia 
is considered one of the major obstacles of RT, it is necessary to proceed with experimental 
studies that allow the specific targeting of hypoxic cells , as well as increasing  their oxygenation 
status, leading to increased radiosensitivity and elimination [64].  
 
1.7 Epigenetics and cancer 
Epigenetics is common known as a set of heterodynamic and hereditary changes in 
chromatin, which are responsible for chromatin organization and transcriptional genes 
regulation passing through generations without altering the DNA sequence [66]. In normal cells, 
epigenetic mechanism regulate constitutively gene expression to maintain cellular variability 
and identity [67]. Currently, the following epigenetic mechanisms are known: DNA methylation, 
histone post-translational modifications, histone variants and chromatin remodeling complexes 
(Figure. 5) 
Figure. 5 Epigenetic Mechanisms. Schematic representation of several epigenetic mechanisms, namely DNA 
methylation and histone modification, being represented the histone variants, the H2A, H2B, H3 and H4 histone 
cores and chromatin remodeling complexes. (Kindly provided by Lameirinhas, A. unpublished).  
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Several epigenetic alterations in human cancers leads to oncogene activation and 
tumor suppressor genes repression, implicated on tumor initiation and development. Cancer 
progression is mediated by epigenetic alterations including, aberrant DNA methylation and 
histone modifications [67]. Therefore, human chromatin is composed by DNA chain coupled 
with histone proteins organized in four cores, such as H2A, H2B, H3 and H4 around histone 
octamer. These specific proteins can acquire particularly post-translational covalent alterations, 
in N-terminal tails, such as methylation of arginine’s or lysine’s residues (mono-, di- or 
trimethylated), as well as acetylation or phosphorylation, the most studied histone modifications 
[68, 69]. Moreover, histones are classified according to the correlation with global transcript 
dynamics, which have highly impact on cancer development, emerging as potential biomarkers 
on oncology research [70]. Some of them are correlated, according to the methylation status, 
with transcriptional activation, such as, the most studied histone 3 lysine 4 (H3K4) and histone 
3 lysine 36 (H3K36), in opposition to, histone 3 lysine 9 (H3K9) and histone 3 lysine 27 (H3K27) 
which are related with transcriptional repression [71, 72]. 
Remarkably, histone methylation is a frequent event on cancer, and its dynamic 
transition plays an important role on transcriptional regulation of several signaling pathways 
influencing the cell cycle, metabolism and overall tumor aggressiveness skills [73]. Accordingly, 
histone lysine demethylases (KDMs) and lysine methyltransferases (KMTs) are the epigenetic 
enzymes that regulate this whole entire process. Thus, KMTs which modifying the histones 
through the insertion of methyl groups, are subdivided in two major classes – with or without 
Su(var)3-9, E(z) (enhancer of zeste) and trithorax (SET) domain [74, 75]. In opposition, 
methylation is tightly specific removed by corresponding KDMs which are also subdivided in 
two major subgroups, including lysine specific demethylase 1 (LSD1), the first histone 
demethylase discovered, containing a flavin adenine dinucleotide (FAD) – dependent domain 
and the other group that encompass the enzymes 2-oxoglutorate-dependent dioxygenase 
superfamily. This group is composed with 7 KDMs subfamilies (KDM2-KDM8), with a Jumonji 
C domain (JmjC) which include oxygen molecule and Fe2+ as cofactor to catalyze the 
demethylation process [74, 76]. Further, these changes both regulate the genetic and 
epigenetic machinery and can be regulated by them, making the entire remodeled process 
dynamic [77].  
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1.8 Role of histone demethylases Jumonji c domain family in hypoxia 
Hypoxia, reported as frequent event on solid tumors and related with increased tumor 
aggressiveness, leads to overall genetic instability (Figure. 6). Thus, activation of the main 
hypoxic mediator transcription factor – HIF-1α – induces several cellular adaptions extensively 
studied, including JmjC-KDMs overexpression through HRE binding sites on DNA sequence 
(G/ACGTG) [78]. It is described the KDM3A, KDM4B, KDM4C (tightly reported in EC [79]), 
KDM6B, KDM2B, KDM5B and KDM5C overexpression, which leads to gene expression 
regulation, associated with a decrease on histone methylated specific markers [80, 81]. Histone 
demethylation play an important role in chromatin remodeling as posttranslational modifications 
and some KDMs are known as direct HIF-1α target. 
Several studies have identified hypoxic genome binding sites for specific key regulators, 
namely JmjC-KDMs, some of them proposed as novel therapeutic targets for several cancer 
models. Accordingly, Ikeda et al. demonstrates that KDM3A/JMJD1A, specific remodeler of 
methylated H3K9, were tightly regulated by HIF-1α under hypoxia conditions [82]. These 
dynamic alterations lead to anti-apoptotic phenomenon, invasive and pro-angiogenic 
properties, cell migration and aggressiveness characteristics, inducing gene transcription 
activation and subsequent signaling pathways regulation, in order to adapt to these changes 
[83, 84]. Moreover, KDM4 subfamily, major target demethylases of H3K9 and H3K36, which 
are responsible for repression or activation of gene transcription, respectively, is important in 
cancer initiation and development, being also associated to hypoxia status, particularly 
KDM4C/JMJD2C [85, 86]. KDM6B, affecting demethylation of H3K27, is previously described 
on the literature with critical role in hypoxic signaling pathways [87, 88]. These main JmjC-
KDMs highlight the importance of epigenetic regulation in hypoxia through HIF-1α signaling 
pathways, being responsible for several phenotypic changes that contributing to disease 
progression.  
Although many others JmjC-KDMs induced at low oxygen levels have been described 
and reviewed, including KDM2 [89], KDM7 [90, 91] and KDM5 [92] subfamily, three of these 
mentioned above, KDM3A, KDM6B and KDM4C [85, 87] are strongly correlated with the 
hypoxic status of the tumor, being induced by oxygen concentration and also regulated by HIF-
1α protein. Their upregulation results in a decrease of transcriptional silencing methylated 
histone markers, including histone 3 lysine 27 trimethylated (H3K27me3) and histone 3 lysine 
9 trimethylated (H3K9me3). These histone marks have an important role in transcriptional 
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regulation of oncogenes altering several signaling pathways related with cell cycle arrest, DNA 
repair, proliferation, migration, invasion and cancer development [81, 93]. 
 
 
1.9 Emerging novel epigenetic targets implicated in radiotherapy response 
Chromatin remodeling by epigenetic alterations has been seen as a crucial event in 
gene expression regulation and consequently in phenotypic alteration, resulting in functional 
and structural changes of human genome. Cancer, a deadly disease depending on the type 
and clinical stage, is a result of genetic and epigenetic cellular alterations [94].  
RT is a common gold standard treatment in several cancer models. This therapy works 
mainly through molecular changes of the tumor mass, including dynamic induction of cell cycle 
arrest, DNA damage induction through accumulation of DSB, metabolic mediation through 
hypoxic sites and cell proliferation and apoptosis regulation. When these processes acquire 
escape mechanisms, therapies fail and tumor become resistant, resulting in poor prognosis 
and low overall survival rates of cancer patients. Although RT contributes strongly to cancer 
treatment, the prognostic value remains often poor and with tendency to recurrences or 
Figure. 6 JmjC-KDMs domain family overexpression through HIF-1α-dependent manner. Under low levels of 
oxygen, HIF-1α mediates histone demethylases expression, a 2-oxoglutorate-dependent dioxygenase superfamily 
with O2 and Fe2+ co-substrate. These epigenetic modulation leads to several cell-induced phenotypic changes, 
resulting in overall cancer progression. Abbreviations: CBP/p300, complex cAMP response element-binding protein/ 
p300 protein; HIF, Hypoxia-inducible factors; HRE, Hypoxic responsive elements; JmjC-KDMs, Histone lysine 
demethylases, Jumonji c domain family.  (Macedo-Silva. C, unpublished).  
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emergence of a second tumor in long-term. Thus, resistance to RT has been a serious obstacle 
in the treatment of several primary tumors [95].  
New therapeutic targets involving particularly epigenetic molecules have shown 
promising results from the discovery of novel potential biomarkers that improve disease 
outcome. Epigenetics coupled with genetic alterations strongly contributes to cancer initiation 
and development, through transcriptional activation of oncogenes and correspondent 
repression of tumor suppressor genes [96]. Several studies have demonstrated, in the last 
decades, promising target therapies with epigenetic agents highlighting the importance of this 
upstream regulation [97]. These advances in oncology research include approved epigenetic 
targeting drugs for reverse DNA malignant methylation and histone onco-modifications, as 
potential radioresistant reversers. These studies have as main aim revert epigenetic alterations 
since they are dynamic and alterable in the cellular regulation [98]. 
Firstly, DNA methylation comprising the main cellular regulation processes in DNA 
transcription with the addition of methyl groups at 5’ position on gene promoter through DNA 
methyltransferases (DNMT’s), including DNMT1, DNMT2 and DNMT3a/b [99, 100]. Thus, DNA 
methylation has been described to have a critical role in cancer development [99]. Recently 
has emerged potential target therapies against this epigenetic event, controlling the activity of 
specific DNMT with inhibitors (DNMTi) namely in radio- and chemotherapeutic approaches 
[101]. Additionally, histone acetylation and methylation are also potential targets for cancer 
therapy [100, 101]. Studies with histone deacetylates inhibitors (HDACi) in combination with 
DNMTi, namely Azacytidine, have shown a tightly therapeutic approach, particularly in EC, 
which has CRT as novel primary treatment for advanced stages [102-104].  
 
1.10 Highlights of chromatin modulation and HIF-1α interaction on target 
therapies approaches 
Knowing that hypoxia in one the main forms of RT resistance in many types of primary 
tumors, a strong contributor to tumorigenesis and cancer progression, it has been urgent to 
find potential target therapies in order to reduce tumor aggressiveness properties through HIF-
1α-dependent manner [59]. 
As epigenetic changes are tightly correlated with therapeutic applications as mentioned 
above in section 1.9, some of them are also implicated in hypoxia regulation through HIF-1α 
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binding, promoting hypoxia-induced genes transcription and consequently affecting therapy 
response. These epigenetic regulation includes enzymes such as histone acetyltransferases, 
(HATs, e.g. complex cAMP response element-binding protein/p300 protein (CBP/p300)) and 
histone deacethylases (HDACs), generally transcriptional activators and repressors of 
acetylation, respectively. Moreover, oxygen suppression also activates KDMs, particularly 
superfamily JmjC-KDMs, intrinsically related with hypoxic status and oxygen molecule, 
resulting frequently in overexpression of activating markers (H3K4me3) and downregulation of 
repressing markers (H3K9me3 and H3K27me3), representing active euchromatin and inactive 
heterochromatin, respectively [105].  
Some studies have shown the importance of hypoxic-inducible KDMs as target 
therapeutic molecules in several cancer models. Accordingly, KDM3A described as highly 
expressed in cancer cells, such as renal and colorectal cancer, has been correlated with 
hypoxia status and HIF-1α induction, being a promising therapeutic target as demonstrated by 
Ikeda et al. in multiple myeloma cancer cells [82]. Other JmjC-KDMs direct HIF-targets, such 
as KDM4B and KDM5B has been also described as promising therapeutic targets [106]. In 
glioblastoma cells, a characteristic hypoxic tumor, KDM5 subfamily was identified as being 
important for development and growth of these tumors [107]. Their specific inhibition in 
combination with cytotoxic drugs improves overall survival rates mediating cell cycle arrest and 
apoptotic induction [107]. KDM6 subfamily is also related with hypoxic tumor microenvironment 
regulation, in particular KDM6B having a potential role on carcinogenesis process [88].  
Remarkably, HIFs, particularly HIF-1α, being the main oncogene activators during 
hypoxic signaling pathways and correlated with epigenetic regulation, particularly JmjC-KDMs, 
as described in several experimental studies [72, 108]. Thus it is crucial to develop therapeutic 
approaches targeting these epigenetic enzymes in order to improve overall patient’s survival 
rates. 
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Currently, EC is an aggressive malignancy with few therapeutic options and poor 
outcome. Thus, the study of new therapeutic targets that allows to improve survival rates, as 
well as the prognosis of these patients is urgently needed.  
 RT, a standard therapy for advanced esophageal tumors, although presenting strong 
benefits in treatment outcome with increase overall survival rates, is sometimes ineffective in 
resistant tumors. Thus, hypoxia, a metabolic condition present in a large range of primary 
tumors, constitutes a foremost limitation in response to DNA damage-induced radiation, being 
the major cause of radioresistant tumors.   
Thus, the main goal of this study was to understand the influence of epigenetic 
regulation - induced hypoxia in esophageal therapy response. Specific aims comprise: 
 
• Characterize JmjC-KDMs (specifically, KDM3A, KDM6B and KDM4C) in clinical 
pathological samples (ESCC and normal esophagus paraffin tissues) and also 
in vitro models with ESCC cell lines, studying their correlation with HIF-1α 
association.  
• Assess the RT response in ESCC cell lines at hypoxic conditions namely low 
oxygen levels and HIF-1α activation through CoCl2 addition. 
• Evaluate the effect of JmjC-KDMs activity inhibition in radiosensitivity of ESCC 
cell lines 
• Determine the effect JmjC-KDMs activity inhibition at hypoxic microenvironment 
in cell cycle and DNA repair capacity, as well as in phenotype aggressiveness.  
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3.1 Clinical tissue samples 
To characterize the KDMs (protein family, JmjC) expression in EC, we collected 69 
ESCC tissue samples from pathological anatomy department at the Portuguese oncology 
institute of Porto, Portugal, between of 2007-2016. 69 ESCC tissue samples were included in 
a tissue microarray (TMA), and from each of them were collected 3 cores from formaldehyde 
fixed paraffin embedded (FFPE) tissue selected block. A total of 20 normal tissues samples 
collected from total gastrectomy’s between 2015-2017, were used as controls. 
 
3.1.2 Immunohistochemistry 
Firstly, it is important to note that one of the antibodies of the KDMs followed mentioned 
on this study – KDM4C – could not yet be optimized for this assay. Therefore, 
immunohistochemistry (IHC) was only performed for KDM3A, KDM6B and HIF-1α proteins. In 
the future, we intend to complete the study with an evaluation of KDM4C through IHC 
performance. 
The IHC was performed using the NovoLink TM Max Polymer Detection System (Leica 
Biosystems, Germany). Briefly, the experimental procedure begins with deparaffinization and 
rehydration of histological slides. Afterwards, antigen retrieval was performed at microwave 
during 20 minutes in specific buffer, depending on the protein studied, as described on 
Supplementary Table. 1, Appendix. II. Next, followed the inactivation of the endogenous 
peroxidases activity in 3% hydrogen peroxide (H2O2) during 10 minutes, the unspecific bindings 
were blocking with horse serum (1:50 dilution) during 20 minutes at room temperature. After, 
the slides were incubated overnight with primary antibody at respective optimized dilution 
(Supplementary Table. 1, Appendix. II). Then, incubation of slides is carried out with the post 
primary block, following the polymer solution during 30 minutes each one. The enzymatic 
reaction with 3,3’-Diaminobenzidine (DAB, Sigma-AldrichTM, Germany) is the next step in order 
to stain the positive areas. Hematoxylin was used as contrast agent and, finally, mounted was 
done with Entellan® (Merk-Millipore, Germany). 
The analysis of immunoreaction was performed by a pathologist according to a semi-
quantitative method. The IHC analysis taking into account the extension (0: <1%; 1: 1-10%; 2: 
10-50%; 3: >50%) and intensity (0: negative; 1: weak; 2: moderate; 3: strong) of each protein 
staining. Then, the combination of extension and intensity was done and the final score ≥3 was 
used to define positive cases.  
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3.2 Cell lines and cell culture  
 In order to study the behavior of the esophageal tumors, particularly the most frequent 
subtype ESCC, in vitro studies were performed using three ESCC cell lines, Kyse 30, OE-21 
and Kyse 410, obtained from American Type Culture Collection (ATCC, USA). Kyse 30 and 
Kyse 410 were kindly provided by professor Fátima Baltazar, from Life and Health Sciences 
Institute, Braga, Portugal and OE-21 was also kindly provide by Fazlur Rahman Talukdar, PhD, 
from International Agency for research on Cancer World Health Organization, Lyon, France. 
All cells were growth in RPMI-1640 medium (Biochrom, MERK, and Germany) supplemented 
with 10% of fetal bovine serum (FBS, Biochrom, MERK, and Germany) and 1% 
penicillin/streptomycin (GBICO, Invitrogen, USA). For cell detach TrypLETM Express solution 
(GIBCO®) at 37ºC were used. Cells growth was done in an incubator at 37ºC with an 
atmosphere of 5% CO2. To ensure optimum conditions in all experiments, mycoplasma was 
periodically tested from cell growth medium using TaKaRa PCR Mycoplasma Detection Set 
(Clontech Laboratories,Mountain View, California, EUA). 
These 3 cell lines differ in cell differentiation features, with Kyse 30 being obtained from 
a well differentiated cell carcinoma; OE-21 was established from a moderately differentiated 
tumor and Kyse 410 derived from a more aggressive and invasive carcinoma with poorly 
differentiated feature. These particular characteristics of each cell line were taken into account 
for all tests performed below.  
  
3.2.1 Induction of hypoxia status 
It is described that a hypoxic tumor microenvironment influences RT response, in 
particular due to HIF-1α pathway upregulation. In order to mimetize tumor hypoxic behavior, 
cells were placed under hypoxic conditions (50 µM CoCl2, low O2 levels), mimicking what 
happens at a molecular level in a tumor microenvironment, always compared to a control 
condition, normoxia, maintained at basal condition 21% O2 levels (Figure. 7). 
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HIF-1alpha chemical induction with CoCl2  
 HIF-1α expression is a crucial condition at hypoxic tumor regions, being involved in a 
set of changes at the cellular level, including RT response. It is known, as already described 
on chapter I, that some metals, namely the cobalt ion, can mimic the hypoxia effect, by blocking 
the binding between the VHL protein and HIF-1α, thus preventing its degradation (Figure. 8) 
[62]. Thus, for HIF-1α expression induction, our cell lines were treated with 50µM CoCl2 solution 
to perform the several functional assay.  
  
 
 
Figure. 7 Schematic representation of tested condition to hypoxia induction status. CoCl2 supplementation 
and hypoxic chambers. 
 
Figure. 8 Schematic representation of CoCl2 action: inhibition of pVHL binding to HIF-1α, preventing HIF-1α 
degradation. Abbreviations: CBP/p300, complex cAMP response element-binding protein/ p300 protein; HIF, 
Hypoxia-inducible factors; HRE, Hypoxic responsive elements; PAS domain, Per-Arnt-Sim domain; pVHL, Von 
Hippel Lindau protein;  
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Hypoxia induction by airtight chambers  
 To achieve hypoxia conditions, ESCC cell lines were grown at 0-1% O2 for all cellular 
assays performed, with the same incubation times as in CoCl2 treatment. For this condition, 
ESCC cell lines were placed at airtight hypoxic chambers at 0-1% O2 during experimental time 
in an incubator at 37ºC. For that, hypoxic chambers were saturated with 95% N2 and 5% CO2. 
In the experimental procedure, esophageal cell lines were treated with 50 μM CoCl2 
and in parallel maintained under hypoxia conditions with an atmosphere about 0-1% O2 and 
tested treatments lasting 24 h, 48 h and a maximum of 7 days. After these treatments, the 
presence of HIF-1α was confirmed at the protein and transcript level. 
 
3.2.2 Cell lines characterization: transcript deregulation assess 
 
RNA extraction, cDNA synthesis and quantitative RT-PCR  
 To assess the ESCC cells transcript at baseline levels or under tested conditions, before 
and after RT, total RNA was extract by a ribozol reagent method. Briefly, the cell pellets were 
suspended and homogenized in TripleXtractor (GRiSP ®) with help of fine needle and 
incubated 5min. Next, chloroform was added to samples, incubated 3 min following 
centrifugation at 10,600 rpm for 15 minutes at 4ºC. Then, an aqueous phase was collected and 
nucleic acid was precipitate with isopropanol during 10min, followed centrifugation at 10,600 
rpm during 10 minutes at 4ºC. Lastly, follows purification steps with two washes of ethanol 75% 
and pellet dry, RNAs were eluted in an RNA storage solution.  
 Total RNA was quantify using NanoDrop Lite Spectrophotometer (Nanodrop 
Technologies, DE, USA). This process allows obtained a quantity of nucleic acids in ng/μL and 
an absorbance ratio A280/A260 to verify the sample quality.  
 Next, in order to characterize transcript levels of target genes in our cell lines, reverse 
transcription was done from 1000ng RNA through a Revert Aid RT Kit (ThermoScientific Inc.), 
according to the procedure instructions. Briefly, the quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) was performed in 396-well plates LightCycler480II 
(Roche) with 450ng of previously synthetized complementary DNA (cDNA) in addition with 
Xpert Fast SYBER Mastermix Blue (GE22.2501, Grisp) and 0.3-0.5µl primers mix. The amount 
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and annealing temperature of the specific primers used are described in Supplementary 
Table.2, Appendix. II. All sample were running on in triplicates. To analyze the results, the 
relative transcript levels of each specific target gene were normalized to the housekeeping 
gene, beta glucuronidase (β-GUS), using ΔΔCt method as described below in Figure. 9. 
Additionally, the relative expression levels were normalized to the control condition in each 
experience.  
 
 
 
  
 
3.2.3 Cell lines characterization: protein expression 
 
Protein extraction & quantification 
To determine the levels of proteins expression, total protein extraction were performed 
from ESCC cell lines under specific conditions. From T25 culture flasks previously washed with 
cold phosphate buffered saline 1X (PBS 1X), the cells were scraped in Kinexus lysis buffer 
supplemented with protease inhibitor cocktail,  following sonication on ice for 5 cycles of 20 
seconds ON and 20 seconds OFF by a Bioruptor® Standard (Diagenode, Philadelphia, PA, 
USA) . Finally samples were centrifuged at 13,300 rpm during 30 minutes at temperature about 
4ºC. To determine the amount of HIF-1α nuclear protein, the nuclear protein were extracted 
using nuclear extract kit (Active Motif) according to manufactures procedures.   
Then, protein concentration on our samples, were determined using the Pierce BCA 
Protein Assay Kit (Thermo Scientific Inc.), according manufacturing instructions.  
 
Western blot  
A total of 30µg protein was separated on 8% and 12.5% polyacrylamide dodecyl-sodium 
sulfate gels (SDS-PAGE), according to the highest or lower protein weight, respectively. Next, 
protein was transferred onto an polyvinylidene fluoride (PVDF) membrane, previously activated 
with methanol (Bio-Rad), using a Tris-Glycine buffer 1X buffer on Trans-Blot Turbo Transfer 
ΔΔCt = (ΔCt Target Gene – ΔCt Reference Gene) – (ΔCt Target Gene – ΔCt Reference Gene) 
Control Condition Tested Condition 
Figure. 9 Description of ΔΔCt method. 
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system (Bio-Rad) at 25V and 1.3 mA during 10 minutes. Prior to immunoblotting with antibody 
of interest at appropriate dilution (see antibodies characteristics in Supplementary Table.3, 
Appendix. II, membranes were blocked in 5% bovine serum albumin (BSA , Santa Cruz 
Biotechnology), for 1h at room temperature. After primary antibody, membranes were 
incubated with specific horseradish peroxidase secondary antibody, for 1h at room 
temperature. Lastly, the results of immunoblotting were visualized using chemiluminescence 
technique (Clarity WB ECL substrate, Bio-Rad). The β-Actin or H3 were used as loading control 
and the results were quantified by a principle of optical densitometry using the ImageJ software 
analysis (version 1.6.1, National Institutes of Health).  
 
Immunofluorescence 
 The cellular localization and expression of some proteins were assessed by 
immunofluorescence (IF). For all ESCC cell lines, at corresponding tested condition, IF were 
performed for KDM3A, KDM6B and KDM4C and the respective histone markers, H3K9me3 
and H3K27me3, as well as for a DNA damage repair antibody, namely phosphorylated H2A 
histone family member X (γ-H2AX). For that, cells were seeded at 3 x 104 cells/mL in a cover 
slips inserted at 24-well plates and allowing to adhere at 37ºC, 5% CO2.Then, cells were treated 
with 50 μM of CoCl2 or incubated at hypoxic chambers, during 24h. After 24 hours the IF 
staining were performed. Briefly, cells were washed in PBS 1X followed fixation with 4% 
paraformaldehyde (PFA) for 10 minutes and permeabilization with 0.25% Triton X-100 solution 
in PBS 1X for 15 minutes. Then, cell blocking with 5% BSA during 30 minutes were done, 
followed primary antibody incubation, at specific dilution described on Supplementary table.3 
(Appendix II), overnight at room temperature. 
The expression of γ-H2AX was assessed in different time points after RT, namely 0h, 
0.5h, 2h and 4h, where γ-H2AX antibody incubation were performed during 1h at room 
temperature.  
After primary antibody incubation, cells were incubated with secondary antibody anti-
rabbit immunoglobulin G (IgG) Alexa FluorTM 488 goat (A11008, Invitrogene) and anti-mouse 
IgG- fluorescein isothiocyanate (FITC) goat (SLB4878, Sigma-Aldrich™) for KDM6B and γ-
H2AX and for KDM3A and KDM4C, respectively. The incubation with anti-rabbit IgG-
Tetramethylrhodamine (TRITC) (T6778, Sigma-Aldrich™) were done for histone markers 
(H3K9me3 and H3K27me3). Then, after 1h, cells were stained with 4’,6-diamidino-2-
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phenylindole (DAPI) (AR1176, BOSTER Biological Technologies) and pictures were taken in 
fluorescence microscope Olympus IX51 with a digital camera Olympus XM10 using CellSens 
software. 
 
Immunocytochemistry 
Immunocytochemistry (ICC) was performed to evaluate HIF-1α expression through 
Novolink™ Max Polymer Detection System (Leica Biosystems, Germany). The cells were 
plated at 3 x 104 cells/mL in a cover slips on 24-wells plates. Then, ESCC cells were incubated 
with 50µM CoCl2 and hypoxia condition during 24h. As control conditions, ESCC cells were 
growth during 24h at 21% O2 (normoxia). After that, cells were fixed in 4% PFA and 
permeabilized in 0.25% Triton X-100 solution for 10min and 15min, respectively. Endogenous 
peroxidases activity was blocked with 3% H2O2 for 10 minutes, followed blocking in1:50 horse 
serum (Gibco) during 20min. Then, cells were incubated with primary HIF-1α antibody (1:250 
dilution, ab1, Abcam) overnight, on a wet chamber at room temperature. Next, cells were 
incubated with post primary block followed polymer for 30 minutes, each one, before 3, 3′-
diaminobenzidine (DAB, Sigma-Aldrich™, Germany) for 10 minutes. Lastly, cells were 
counterstaining with hematoxylin and mounted in aqueous mounting medium (Aquatex®, 
Merck, Germany). Pictures were taken in a microscope Olympus BX41 with a digital camera 
Olympus U-TV0.63XC using CellA software.  
 
3.2.4 Histone demethylases inhibition by IOX1 ≥ 97% (HPLC), Sigma -
Aldrich 
In order to determine the influence of KDMs (2-oxoglutarate-oxygenase (2OG) 
dependent JmjC family) on RT response, a 2-oxoglutarate oxygenase inhibitor (5-Carboxy-8-
hydroxyquinoline, IOX1, Sigma-Aldrich, Germany) was used. IOX1 inhibitor binding to active 
site of large set of KDM’s preventing the demethylation of the specific histone marks Figure. 
10. 
Accordingly, KDM3A and KDM4C demethylases H3K9me3 and KDM6B the H3K27me3 
[109]. In the experimental procedures ESCC cells were exposed IOX1 inhibitor during 24h, 48h 
and 7 days, depending on the assay performed.  
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Figure. 10 Schematic representation KDM (Jumonji c Domain) Inhibitor (IOX1). IOX1 leads to high levels of 
methylated histone markers. Abbreviations: IOX1, 2-oxoglutarate oxygenase inhibitor; KDM, histone lysine 
demethylase. 
 
 
  
 
3.2.5 Cell viability assay 
To determine the effect of IOX1 inhibitor in cell viability during the different functional 
assays performed in this work, firstly the half maximal inhibitory concentration (IC50) was 
determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenultetrazolium (MTT) assay (Sigma-
Aldrich, Schnelldorf, Germany). MTT assay is a direct measure of cell viability, measuring the 
mitochondrial activity. This assay is based on the capacity that viable cells have to incorporate 
MTT and mitochondrial enzyme succinate-dehydrogenase converted them in a purple colored 
formazan product. Briefly, cells were plate at 1 x 104 cells/mL density in 96-wells plates. Then, 
after adhered, cells were treated with a concentrations range of IOX1 inhibitor from [0-50] µM 
in RPMI-1640 complete medium for 24h, 48h and 7 days.  
Then, at specific time point, 5 μg/mL MTT was incubated at 37ºC during 1h, the violet 
crystals formed are dissolved with dimethyl sulfoxide solution (DMSO, Sigma-Aldrich) and 
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spectrophotometric measurement was done at 540 nm (reference wavelength at 655nm) in a 
microplate reader (Fluostar Omega, BMG Labtech, Offenburg, Germany). MTT was performed 
at 0 hours, time at which IOX1 inhibitor was given to EC cells. 
 
3.2.6 Colony formation assay: cell survival curves 
Clonogenic assay are the main known technique for determining cellular radiosensitivity 
through biological applied mathematical models [110]. Colony formation assay was performed 
to evaluate the cellular response under a spectrum of radiation doses. This technique allows 
to determine the capacity of a single cell form a colony (≥50 cells) [111]. The test conditions 
used to this in vitro assay was CoCl2 and hypoxia treatment compared to normoxia and IOX1 
+ CoCl2 and IOX1 + hypoxia treatment compared to respective hypoxia or CoCl2 control 
conditions, all of them in the presence of RT.  
Briefly, ESCC cells were plate in 6-well plates at specific concentration for each condition 
and each cell line as described in Supplementary Table. 4 (Appendix II). Then, 50µM CoCl2 
treatment or hypoxia induction were done. After 24h, ESCC cells were exposed to radiation in 
a range between [0-8 Gy] and incubated at 37ºC until 7 days of experiment. Cells were 
irradiated by 6MV X-rays linear accelerator photon Truebeam (Varian Medical Systems, 
California, USA) with the irradiation field measures of 25 x 25 cm2. Additionally, the dose rate 
at monitor units (MU) applied was 600 MU/min. For IOX1 inhibitor experiments, behind 24h of 
CoCl2 and hypoxia stimulation, ESCC cells were treated with 20 µM IOX1 in complete RPMI-
1640 medium during 24h followed by [0-8 Gy] radiation treatment and 37ºC incubation until 7 
days of experiment. 
Lastly, cells were stained with Giemsa for colonies counting. Then, cells were washed in 
PBS 1X for 5 minutes following fixation in methanol during 10 minutes under shaking. Next, 
cells were stained in 25% Giemsa solution during 20 minutes under shaking. Finally, cells were 
washed with distilled water and allow to dry. Colonies were counted on microscope Olympus 
IX51 and the statistical data and cell survival curves analysis were done by RAD ADAPT 
software system [112]. RAD ADAPT analysis taking into account the number of cells plated 
and the number of colonies counted, by single hit multi-target model (SHMT), S(D)= PE * (1-
(1-exp (-D/D0))n) . Thus, the statistical parameters evaluated were D0 (mean lethal dose, the 
dose that reduces survival to 37%), Dq (quasi-thereshould dose), n (extrapolation number), 
survival fraction at 2 Gy (SF2) and sensitize enhancement ratio (SER), demonstrated on 
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Figure. 11 Statistical parameters of clonogenic assay used in cell survival curves. 
Figure. 11. The p value of the curve was calculated taking into account the value of D0 of each 
condition. 
 
 
 
 
 
 
 
 
  
3.2.7 Apoptosis evaluation 
In order to complement cell behavior studies after IR apoptosis assay were performed. 
Briefly, 2x104 cell/mL of cells were seeded on 24-well plates and incubated 37ºC to adhere. 
Then, 50 µM CoCl2 and hypoxia induction were performed during 24h. Additionally, when 
applicable 50 µM IOX1 treatment were performed during 24h before 2 Gy radiation. After 24h 
of 2 Gy radiation the Cell-APOPercentage apoptosis assay kit (Biocolor, United Kingdom) were 
performed according the manufacturing instructions. Then, cells were incubated with 300µl/well 
of APOPercentage dye solution at ratio 1:20 respectively, during 30min at 37ºC. Next, cells 
were washed with PBS 1X and detached from well plate with TrypLeTM Express (GBICO, 
Invitrogen, USA) at 37ºC. After that, APOPercentage dye release reagent was added and plate 
were vigorously agitated during 15min, following colorimetric measurement at 550nm with 
620nm reference filter (Fluostar Omega, BMG Labtech, Offenburg, Germany).  
 
3.2.8 Wound healing analysis 
Since it is described that hypoxia and consequently increased HIF-1α expression 
promotes aggressiveness and tumor progression, we investigated how ESCC cells under these 
conditions acquired greater migration capacity. Briefly, ESCC cells were seeded on 6-well 
plates, at a concentration of about 5 x 104cells/mL and, then, were exposed to 50 µM CoCl2 or 
hypoxia during 24h. Then, when applicable, cells were treated with 50 µM IOX1 24h previous 
radiation. When cells reach an optimal confluence above 95% two parallel “wounds” in each 
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Figure. 12 Schematic representation of wound healing assay and statistical parameters calculation.  
 
 
well (initial slope) were done followed by 2Gy radiation. At this time point (0h) and 24h later, 
pictures were taken using an Olympus IX51 inverted microscope with a digital camera Olympus 
XM10.Then, relative migration distance was analyzed by beWound - Cell migration tool 
(Version 1.5) and the percentage of cell migration was calculated as described in Figure. 12. 
 
 
3.2.9 Single-cell gel electrophoresis (Comet assay) 
Since the radiobiology and the efficacy of radiotherapeutic treatment depended on the 
DNA chain damage repair, in addition to the γ-H2AX analysis, we were determined the DNA 
damage by comet assay analysis. Following the same line of treatment described above for 
apoptosis and wound-healing migration assays, after 50 µM CoCl2, hypoxia induction and 50 
µM IOX1 when applicable, ESCC cells were treated with 2 Gy IR at 0h, 0.5h and 2h time points.  
 Briefly, as described on Figure. 13, at appropriate time points, cells were harvested by 
trypsinization and then 30,000 counted cells were re-suspended in 0.5% low melting point 
agarose (LMA) (w/v) and immediately placed on a sheet, which was previously covered with 
1% normal melting point agarose (NMA) (w/v) layer, covered with a coverslip and incubated 30 
minutes at 4ºC for polymerization. Then, the assessment to DNA molecule was done with a 
lysis buffer, pH 10 (2.5 M NaCl, 100 mM ethylenediamine tetraacetic acid (Na2EDTA), 10 mM 
 III – Materials and Methods 
Esophageal cancer therapy response: role of hypoxia in epigenetic mechanism regulation 
 36 
Figure. 13 Representative scheme of single-cell gel electrophoresis, comet assay procedure. Abbreviations: 
LMA, Low melting point agarose; NMA, Normal melting point agarose. 
 
Tris base, 1% Triton X-100) at 4ºC for 2 hours in the dark. After that, cells were incubated 40 
minutes with running buffer, pH=13 (300 mM NaOH, 1 mM Na2EDTA) at 4ºC to DNA uncoil. 
The run was performed during 30 minutes at 21V, 300 mA. Lastly, sheets were incubated in a 
neutralization buffer (0.4 M Tris-Base, pH 7.5,) for 10 minutes and fixated in 100% ethanol 5 
minutes twice. Follows the staining with Sybr Green (Invitrogen) assembly of the sheets was 
done for later viewing on fluorescence microscope Olympus IX51 using a digital camera 
Olympus XM10 with a CellSens software. Analysis of comets formed was done in detail by 
OpenComet v.1.3.1, plugin of ImageJ software (version 1.6.1, National Institutes of Health) 
[113], obtaining statistical parameters ,such as tail moment that evaluates the DNA % 
fragmentation, thought the multiplication of  tail % DNA and means of head and tail distance. 
A sampling of at least 50 comets should be included in the analysis.   
 
 
 
 
 
 
 
 
 
 
3.2.10 Chromatin immunoprecipitation assay (ChIP) – qPCR 
In order to determine the interaction between HIF-1α protein and KDM’s promoter 
binding in ESCC cell lines, chromatin immunoprecipitation assay was performed. For this 
experience, the antibodies and pair primers were described on Supplementary Tables. [5-6] 
(Appendix II). For the same experimental conditions were those mentioned above in functional 
assays 10 million cells were cultivate at 37ºC, 5% CO2 on incubator. This functional assay 
incorporates a set of subsequent events beginning with the crosslink of the protein to DNA on 
the nucleus. For that, cells in culture flask were incubated with 1% formaldehyde for 8 minutes 
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at room temperature. Next, the action of formaldehyde was blocked with 2 mL Glycine 10X at 
2.5M, for 7 minutes at room temperature. Followed two washes with cold PBS 1X, scraping 
with a PBS 1X in 10% protease inhibitor cocktail II (PIC) and centrifugation at 800g, 5 minutes 
at 4ºC were done. The next crucial step was cell lysis, which pellet cells were incubated with a 
cell lysis buffer (10mM Tris-HCl, 10mM NaCl and 0.5% NP-40) for 2 hours at 4ºC with small 
periods of shaking, and then with a nuclei lysis buffer (50 mM Tris-HCl, 10 mM EDTA and 1% 
SDS). Lastly, before proceeding to the chromatin sonication step, a dilution buffer was added 
(16.7 mM Tris-HCl, 167 mM NaCl, 1.2 mM EDTA and 0.01% SDS) to the final volume of 300 
μL. The process of sonication to shear DNA chain was optimized for each cell line, namely for 
Kyse 30 and OE-21 cell lines 15 cycles of 30 sec ON, 30 sec OFF and for Kyse 410 cell line 
30 cycles of 30 sec ON, 30 sec OFF, at 4ºC on Bioruptor® Standard (Diagenode, Philadelphia, 
PA, USA). The final sonicated chromatin product was stored at -80ºC until used. Additionally, 
to confirm the sonication procedure 5 μL of sample, previously digested with RNase A at 37ºC 
during 30 minutes and proteinase K at 62ºC for 2 hours, was run on 2% electrophoresis gel 
agarose, observed in an ultraviolet transilluminator (Molecular Imager® VersaDocTM MP 4000 
System (BioRad, California, EUA), and DNA fragments must be ideally in a range of 300 to 500 
base pairs (bp) as shown on Figure. 14. 
 
Figure. 14 Electrophoresis gel of sonicated chromatin. Abbreviations: bp, basepairs. 
 
Afterwards, proteins are immunoprecipitated in a protein/DNA crosslink as briefly 
demonstrated on Figure. 15. Then, a mix of 50 μL of chromatin, 450 μL of immunoprecipitation 
(IP) dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCL, pH=8.1, 
167 mM NaCl), 20 μL of Magn ChIP protein A+G magnetic beads, (16-663, EMD Millipore, 
USA) and an optimized quantity of antibody referred on Supplementary Table.5, Appendix. 
500 bp_ 
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Figure. 15 Schematic representation of chromatin immune complex beads. 
II was incubated overnight at 4ºC, under constant rotation. Additionally, before protein/DNA 
crosslink, we collected 5μL of chromatin/IP dilution buffer mixture, which will serve as input in 
our experience. In each immunoprecipitation protocol a positive anti-RNA polymerase II 
antibody and a negative normal mouse IgG antibody control were necessary to evaluate the 
assay efficiency. 
 
 
 
 
 
 
 
 
 
 
 
 
After the IP process, consecutive fully washes were carried out with the help of a 
magnetic system (Magma Grip Rack, EMD Millipore, USA), at 4ºC for 5 minutes with rotation. 
In this step we used four consecutive different washes buffer such as,  
• Low Salt wash buffer (500 μL), 0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM 
Tris-HCl, pH=8.1 and 150mM NaCl 
• High Salt wash buffer (500 μL), 0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM 
Tris-HCl, ph=8.1 and 500mM NaCl 
• LiCl wash buffer (500 μL), 0.25M LiCl, 1% NP-40, 1 % Desoxicolate, 1mM and 
EDTA, 10mM Tris 
• TE wash buffer (500 μL), 10mM Tris-HCl, pH=8.0 and 1mM EDTA 
 III – Materials and Methods 
Esophageal cancer therapy response: role of hypoxia in epigenetic mechanism regulation 
 39 
Afterwards, to each tube 100 μL of ChIP elution buffer (1% SDS and 0.1M NaHCO3) 
were added to proceeded digestion with RNase A at 37ºC for 30 minutes and proteinase K at 
62ºC for 2 hours. Lastly, a DNA purification step were performed using a Qiaquick gel extraction 
kit (50928706, Qiagen, Germany) according to manufactures instructions. The finally purified 
DNA samples must be stored at -20ºC until be used on RT-PCR reaction.  
Therefore, to assess the specific post-translational regulation of HIF-1α/KDMs qPCR 
were performed on 396-well plates LightCycler480II (Roche), each sample in triplicates. For 
this we used specific primers of KDM3A, KDM6B and KDM4C at different regions above 
transcriptional starting site (TSS), called A to C depending on base pairs (bp) distance. 
Compelled information is described on Supplementary Table. 6 (Appendix II). In each well 
was put 1.5μL of purified DNA sample, 5μL of Xpert Fast SYBER Mastermix Blue (GE22.2501, 
Grisp) and primer concentration of 0.3 μL, optimized and described on Supplementary Table. 
6 (Appendix II). To analyze the results obtained, statistical data were presented by input 
percentage method through the calculation of CT raw mean (CT Raw = CT-6.644) and the 
percentage of input (%Input = 100*(2^ (CT Raw mean – CT)).  
 
3.2.11 Statistical Analysis 
Statistical analysis was performed using GraphPad Prim 6.0 software (GraphPad 
Software Inc., La Jolha, CA, USA) and to compare different conditions, performed in the 
different in in vitro assays we used non-parametric Kruskal-Wallis test or  Mann-Whitney U test 
with Bonferroni’s correction. Additionally, to compare IHC results of KDMs and HIF-1α 
expression in ESCC and normal esophageal tissues, Pearson´s chi-square or Fisher’s exact 
test were used. In each analysis, the p values were considering significant when the value was 
lower than 0.05. (* p<0.05; ** p <0.01; *** p <0.001; **** p < 0.0001; ns – no significance).  
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4.1 Histone demethylases (Jumonji c domain family, JmjC) as prognostic 
markers in normoxic and hypoxic regions of esophageal cancer clinical 
samples 
4.1.1 Characterization of KDM3A and KDM6B expression in esophageal squamous cell 
carcinoma 
In a series of 69 ESCC tissue samples, specific KDMs expression were characterized. 
Additionally, we assessed also the expression of KDMs in 20 normal esophageal tissues. KDMs 
are altered in several cancer types, namely in EC, being correlated with poor prognosis. Thus, 
we evaluated their expression in our ESCC and normal esophagus tissue cohort. 
In IHC analysis we observed nuclear expression on both KDM3A and KDM6B in ESCC 
tissues. In normal esophageal tissues KDM3A and KDM6B also present a weak nuclear 
expression at basal epithelial cells Figure. 16.  
 
 
In our cohort we observed a significant overexpression of KDM3A (p<0.0001) and 
KDM6B (p=0.0003) in ESCC (68% [47/69] and 45% [31/69], respectively) compared with the 
normal esophagus (10% [2/20] and 20% [4/20], respectively) (Table. 2 and Figure. 17). 
 
Figure. 16 Expression of JmjC-KDMs in normal esophagus and ESCC. Pictures representative of a weak (1+) 
and strong (3+) staining for each condition. (400x magnification). Abbreviations: ESCC, Esophageal squamous 
cell carcinoma; JmjC-KDMs, Histone lysine demethylase, Jumonji c domain family. 
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Normal Esophagus ESCC
n 20 69
KDM3A
Negative (%) 18 (90) 22 (32)
Positive (%) 2 (10) 47 (68)
p value <0.0001
n 20 69
KDM6B
Negative (%) 16 (80) 38 (55)
Positive (%) 4 (20) 31 (45)
p value 0.0003
n 20 69
HIF-1a
Negative (%) 20 (100) 42 (61)
Positive (%) 0 (0) 27 (39)
p value <0.0001
 
 
 
 
 
 
 
 
 
  
 
ESCC, Esophageal squamous cell carcinoma. 
Table. 2 Detailed distribution of KDM3A, KDM6B and HIF-1α expression in normal esophagus and ESCC.  
 
Figure. 17 IHC analysis. A, Distribution of KDM3A and KDM6B expression (%) in normal esophagus and 
esophageal squamous cell carcinoma (ESCC); B, Representative graphs of the staining intensity range from 0, 
+1, +2 and +3, observed for KDM3A and KDM6B. 
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Moreover, IHC evaluation was also performed by defining the intensity of the staining, 
classifying each case in an interval [0, +1, +2, +3], which was determined by the specialized 
pathologist and previously described in methods (chapter 3). Accordingly, in Figure. 17B, in 
KDM3A we observed a greater prevalence of intensity +3 in ESCC compared with the normal 
esophagus where +2 prevails. For KDM6B, a predominance of intensity +2 was depicted by 
controls, whereas a homogeneous distribution mostly between +2 and +3 was found in the 
tumors.  
 
4.1.2 Assessment of hypoxic marker HIF-1α expression in esophageal squamous cell 
carcinoma  
In order to determine the role of hypoxia in ESCC we performed IHC analysis, in 
addition to the KDMs, for HIF-1α protein, which presented an evident nuclear staining (Figure. 
18A).  
 
 
Figure. 18 Expression of HIF-1α in normal esophagus and in ESCC. A, Pictures representative of a weak (1+) 
and strong (3+) staining for each condition. (400x magnification). B, Percentage of positive and negative cases for 
HIF-1α in normal and tumor esophageal samples. C, Representative distribution of staining intensity for esophageal 
squamous cell carcinoma (ESCC) and normal esophagus.  
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As observed in Figure. 18B, HIF-1α was expressed in (39% [27/69]) of esophageal 
squamous tumors (p < 0.0001) (Table. 2). 
Regarding the intensity of staining (Figure. 18B), although we observed intense 
staining in the normal esophagus (value +3), their expression was predominantly at the 
surface of epithelium, contrary to KMDs expression, which was present in epithelial basal 
cells. Thus, the HIF-1α staining was classified as negative in the normal esophagus (Figure. 
18B). Although, in ESCC intensity varied from 0 to +3 greater intensity value (+3) was 
predominant. 
 
4.1.3 Correlation of HIF-1α protein expression with histone lysine demethylases in 
hypoxic regions 
HIF-1α overexpression was associated with the presence of specific KDMs. However, 
only a statistically significant association was observed for KDM3A (p value < 0.05), although 
KDM6B also showed a trend (Table.3). 
 
 
 
 
 
Table. 3 Association of KDMs with HIF-1α in ESCC tissues.  
HIF-1a
Negative (%) Positive (%)
KDM3A
Negative (%) 16 (24) 5 (7)
Positive (%) 26 (38) 21 (31)
p value 0.0488
KDM6B
Negative (%) 27 (40) 10 (14)
Positive (%) 17 (25) 14 (20)
p value 0.0597
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4.2 Hypoxia increases histone demethylase expression, decreasing 
radiotherapy response in esophageal squamous cell carcinoma  
4.2.1 Hypoxia-inducible factor, HIF-1α, expression in esophageal squamous cell 
carcinoma cell lines  
To confirm the impact of HIF-1α in hypoxia and its role in cellular pathways regulation 
we assessed their transcript and protein levels, by qRT-PCR, WB and ICC, respectively 
(Figure. 19).  
 
 
 
Figure. 19 Characterization of HIF-1α expression in ESCC cell lines. A, HIF-1α protein expression in esophageal 
squamous cell carcinoma cell lines by Western blot. B, HIF-1α expression in CoCl2 and hypoxia conditions compared 
to normoxia (21% O2) by RT-PCR, ** p<001; *** p<0.001 C, Nuclear HIF-1α expression in normoxia, 50µM CoCl2 
and hypoxia by immunocytochemistry. D, Nuclear HIF-1α protein expression with 50µM CoCl2 and hypoxia 
compared to normoxia by Western blot. 
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At basal oxygen levels, Kyse 410 cell line presented a higher HIF-1α protein levels, 
(Figure. 19A). Accordingly, this cell line presents a more aggressive phenotype, with poorer 
cellular differentiation than the other studied cell lines. Thus, their behavior is supported by the 
higher HIF-1α levels observed. 
Since, we aimed to understand the role of hypoxia and consequently HIF-1α expression 
in epigenetic regulation and RT response, we firstly performed HIF-1α characterization, either, 
after CoCl2 addition or hypoxia stimulation. Thus, we observed that 50μM of CoCl2 addition and 
low oxygen levels increased HIF-1α expression both at transcriptional (Figure. 19B) and 
protein levels (Figure. 19 C-D). Moreover, increased HIF-1α expression with 50µM CoCl2 and 
hypoxia (0-1% O2) was observed at the nucleus by ICC (Figure. 19C) and WB (Figure. 19D).  
 
4.2.2 Highlights of tumor hypoxia: impact of oxygen levels in radiotherapy response  
 To assess how the low oxygen levels and consequently HIF-1α expression influence 
RT response in ESCC, the colony formation assay was performed. 3 ESCC cell lines were 
treated with 50 µM CoCl2 or stimulated with hypoxia before to IR treatment. Contrary to our 
expectations, not all cell lines responded to all tested conditions for this experimental assay.  
Kyse 30 cell line did not maintain the viability and ability to form colonies with HIF-1α chemical 
inductor – CoCl2. Thus, it was only possible to show the normoxia and hypoxia conditions for 
this line. Moreover, to confirm the presence of HIF-1alpha after single addition of 50 μM CoCl2, 
during the 7 days of colony formation assay, we were also verified through WB, the HIF-1α 
protein expression at these conditions for ESCC cell lines (Supplementary Figure. 1, 
Appendix. III). 
Firstly, at basal status Kyse 410 presented lower RT response than other ones (Figure. 
20A), showing a more resistant behavior. Conversely, the other two cell lines, Kyse 30 and OE-
21, exhibited a similar responsive behavior with higher RT response (Figure. 20A).  
  CoCl2 and hypoxia decreased cellular response to IR, as observed by the statistical 
parameters of the survival curves analysis. Firstly, from the visualization of survival curves, we 
verified a lower dose-response rate with CoCl2 and hypoxia compared to normoxia (control 
condition), with exception of Kyse 410 (Figure. 20B).  
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D0 values (a mean lethal dose) were significantly higher in CoCl2 and/or hypoxia 
conditions compared to normoxia in all cell lines, with the exception of Kyse 410 (Figure. 20C). 
Additionally, Dq values, which represents the radiosensitivity value (quasi-thereshould dose) 
Figure. 20 Cell survival analysis to radiotherapy treatment. A, Cell survival fraction analysis of ionizing radiation 
in esophageal squamous cell carcinoma cell lines studied. B, Cell survival curves for Kyse 30, OE-21 and Kyse 410 
comparing hypoxia and CoCl2 conditions with normoxia. C, Summary table, including statistical parameters studied 
for all conditions tested such as D0, mean lethal dose, Dq, quasi-thereshould dose, n, extrapolation number, SF2, 
survival fraction at 2 Gy, always taking into account the cells seeded in each condition. Abbreviations: PE, plating 
efficiency; S(D), survival dependent of dose SHMT, single-hit multi target 
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tended to be higher in hypoxia for all cell lines (Figure. 20C). In CoCl2 condition only OE-21 
cell line presented higher Dq values (Figure. 20C). Moreover, the survival fraction value at 2Gy 
(SF2), was also higher in CoCl2 and hypoxia compared to normoxia (Figure. 20C). These 
results are in agreement with the assumption that hypoxia and consequently HIF-1α 
overexpression increase tumor radioresistance. 
 
4.2.3 Role of hypoxia in epigenetic modulation: potential influence of HIF-1α in histone 
lysine demethylases, Jumonji c domain family regulation  
4.2.3.1 Assessment of histone lysine demethylases status under hypoxia  
To explore the hypoxic microenvironment effect in epigenetic modulation, the three 
JmjC-KDMs, namely, KDM3A, KDM6B and KDM4C that acts by oxygen-dependent manner, 
were investigated. Thus, assessment of these KDMs in ESCC lines, at basal conditions, 
showed higher KDM3A transcript expression levels than KMD4C and KDM6B (Supplementary 
Figure. 2, Appendix. III). Furthermore, the addition of 50μM CoCl2 and hypoxia induction 
increased KDM3A, KDM4C and KDM6B transcript levels (Figure. 21A), as well as nuclear 
protein expression (Figure. 21B) compared to normoxia, by RT-PCR and IF, respectively.  
Moreover, knowing that these enzymes act as KDMs we evaluate how their respective 
histone markers, namely H3K9me3 and H3K27me3, are affected. Indeed, a H3K9me3 and 
H3K27me3 protein levels decrease was found (Figure. 21C). To confirm the association 
between KDMs respective histone marks levels at conditions defined above, IF co-localization 
was also performed. In CoCl2 and hypoxia conditions, KDM3A, KDM4C and KDM6B (green 
fluorescence) staining was increased while H3K9me3 and H3K27me3 staining was decreased 
(red fluorescence) comparing with normoxia conditions (Supplementary Figures. 3-5, 
Appendix. III). 
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Figure. 21 Effect of hypoxia and HIF-1α activation on JmjC-KDM expression. A, JmjC-KDM domain 
transcriptional levels in esophageal squamous cell carcinoma cell lines, through qRT-PCR, ** p<0.01; *** p<0.001; 
**** p<0.0001. B, Representative images of immunofluorescence, in hypoxic and normoxic conditions, which histone 
demethylases (KDMs) stained with green IgG-FITC antibody and DAPI (blue staining). C, Representative Western 
blot results and density optical quantification for H3K9me3 and H3K27me3. N, normoxia; C, CoCl2, H, hypoxia. 
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4.2.3.2 Influence of hypoxia microenvironment modulation on transcriptional regulation of HIF-
1α and histone lysine demethylases, Jumonji c domain family binding sites    
To evaluate the direct modulation of HIF-1α to HRE binding specific sites of KDM3A, 
KDM4C and KDM6B, ChIP analysis was performed in normoxia, 50µM CoCl2 and hypoxia in 
ESCC cell lines. In hypoxia, a significant HIF-1α binding to KDM3A, KDM4C and KDM6B 
transcriptional sites of several regions above TSS was observed in all cell lines with exception 
of KDM4C A and KDM6B C region in OE-21 and Kyse 410, respectively (Figure. 22). 
In Kyse 30 cell line, CoCl2 condition significantly associated with increased binding of 
HIF-1α to KDM3A A comparing with normoxia condition (Figure. 22). Additionally, in Kyse 410 
a significant increase of this enzyme was found for CoCl2 condition compared to normoxia 
(Figure. 22). In OE-21, a significant KDM3A transcriptional activation was found, as well as of 
KDM4C B region (Figure. 22).  
 
4.2.4 Effect of hypoxia microenvironment in cell aggressiveness markers and their 
implication on radiobiology assumptions 
4.2.4.1 Effect on DNA damage repair after radiotherapy treatment under hypoxia conditions 
Considering that DNA repair is one of the main R’s of radiobiology, we evaluated DNA 
damage repair through of H2AX phosphorylated marker (γ-H2AX), which is the firstly response 
to DSB on cell (Figure. 23A). Additionally, through single-cell gel electrophoresis technique 
(comet assay) we evaluated DNA damage extension caused by IR therapy (Figure. 23B). 
Figure. 22 JmjC-KDMs promoter regulation by HIF-1α protein. Representative graphs of histone demethylases 
regions enriched with HIF-1α – hypoxic responsive elements binding sites in esophageal squamous cell carcinoma 
cell lines, taking into account the percentage of input DNA and the distance to transcriptional starting site, ns – non 
significance; * p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
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In the functional assays performed with IR, cells were irradiated with 2Gy, which is the 
conventional daily treatment dose in EC patients.  
In normoxia condition γ-H2AX (DNA damage repair marker) reaches the highest 
expression peaks at 2 - 4 hours after RT treatment (Figure. 23A). In opposition, with 50 μM 
CoCl2 addition and hypoxia induction, γ-H2AX presents the highest fluorescence intensity 
earlier (Figure. 23A). The highest fluorescence intensity in CoCl2 and hypoxia conditions, 
appears between 0h-30min after RT for all cell lines, excepting to Kyse 30 cell line at CoCl2 
condition which appears 2h after RT (Figure. 23A a1).  
Moreover, in comet assay analysis we assessed the DNA % fragmentation (tail 
moment) at several time points after RT, namely 0h, 30min and 2h for ESCC lines. Low levels 
of oxygen and HIF-1α chemical induction promote less damage compared to normoxia, in all 
ESCC lines studied, particularly in OE-21 cell line (Figure. 23B).  
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 Figure. 23 Assessment of DNA damage response after ionizing radiation in ESCC cell lines. A, 
Representative images of nuclear γ-H2AX expression under normoxic and hypoxic conditions, through 
immunofluorescence. B, Detailed results of comet assay for the same tested conditions represented by microscopic 
images and statistical graphs at different time points after 2 Gy of ionizing radiation, including 0h, 30min and 2h, ns 
– non-significance; * p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.  
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4.2.4.2 Cell cycle checkpoints deregulation after radiotherapy treatment  
Cell cycle redistribution is other fundamental principle of R’s of radiobiology. One of the 
immediately cellular responses to an external damaging agent, namely IR, is the activation 
defense mechanisms such as the cell cycle checkpoints [55]. Thus we assessed cell cycle 
checkpoints changes after RT in a hypoxic microenvironment. 
 We determined the status of tumor protein p53 (TP53), cyclin dependent kinase inhibitor 
1A (CDKN1A), mouse double minute 2 homolog gene (MDM2) and checkpoint clamp 
component A (RAD9A), 30min and 24h after 2 Gy treatment, through qRT-PCR. General trends 
are represented in a summary table in Figure. 24C. 
TP53, CDKN1A, and RAD9A were significantly downregulated in CoCl2 and hypoxia 
compared to normoxia condition 30min after RT (Figure. 24A). However, significant TP53 and 
CDKN1A downregulation, in Kyse 410 and OE-21 respectively, was not found (Figure. 24A). 
In contrast, MDM2 showed a general trend to be upregulated in all cell lines (Figure. 24A).  
Moreover, 24h after RT, TP53 and CDKN1A maintained the same trend of that 30min 
(Figure. 24B), with exception of CDKN1A for Kyse 410. The MDM2 was found downregulated 
in hypoxia, whereas no significant differences were observed in CoCl2 addition when compared 
to normoxia condition (Figure. 24B). Lastly, 24h after RT RAD9A expression did not shown 
significant differences among all the studied conditions, excepting for OE-21 cell line in which 
downregulation was observed (Figure. 24B).  
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4.2.4.3 Evaluation of cell migration behavior and apoptosis levels under hypoxia conditions 
When assessing cell migration capacity, 2 Gy IR significantly decreased cell migration at 
24h in normoxia, except for OE-21 cell line (Figure. 25A-B). Additionally, HIF-1α chemical 
induction and hypoxia stimulation significantly increased the migratory capacity of all ESCC 
lines at 24h after 2 Gy RT (Figure. 25A-B).  
 
 
 
Figure. 24 Evaluation of cell cycle checkpoints deregulation under hypoxic stimulation after IR., Expression 
of TP53, CDKN1A, MDM2 and RAD9A genes after A, 30 min and B, 24h of 2 Gy IR, by qRT-PCR, ns – non-
significance; * p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. C, Summary table representing the global tendency of 
cell cycle checkpoint genes under hypoxic conditions (CoCl2 and hypoxia).  
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Figure. 25 Effect of hypoxia stabilization in cell migration capacity effect after IR treatment. A, Representative 
pictures of cell migration in esophageal squamous cell carcinoma cell lines at CoCl2 and hypoxia conditions 
compared to normoxia, for 0h and 24 hours after 2Gy of ionizing radiation. B, Detailed graphs of cell migration under 
the same previously mentioned conditions. Statistical significance of p value is related to control (normoxia) at least 
of three independent experiments, ns – non-significance; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.  
 IV – Results 
Esophageal cancer therapy response: role of hypoxia in epigenetic mechanism regulation 
58 
Knowing that RT induced cell death, the percentage of apoptosis was assessed in all 
tested conditions after IR (2 Gy). Here in, all cell lines showed a decreased percentage of 
apoptotic cells in both CoCl2 and hypoxia conditions (Figure. 26). Kyse 30, also displayed a 
significant decrease in apoptosis at normoxia conditions (Figure. 26).  
 
 
4.3 Histone demethylase inhibition increases radiotherapy response in 
hypoxic ESCC cell lines 
4.3.1 Cytotoxic effect of 5-Carboxy-8-hydroxyquinoline (IOX1) in esophageal cancer 
cells 
As previously described in chapter 2, the IOX1 was used to inhibit JmjC-KDM family 
activity. Then, to determine cytotoxic effect and IC50 value, MTT assay was performed at the 
time points defined for all assays, specifically at 24h, 48h and 7 days. 
Interestingly, IOX1 did not induce a direct dose-response effect, since cells maintained 
viability in a range of 50-100% without any dose-dependent trend (Figure. 27).  
Thus, with the exception of the colony formation assay where cells were treated with 20 
μM for 7 days, for the subsequent functional assays, cells were treated with 50 μM IOX1 during 
24h or 48h. 
Figure. 26 Effect of hypoxic microenvironment on cell apoptosis after IR treatment.  Representative graphs 
of cell apoptosis percentage for esophageal squamous cell carcinoma cell lines under hypoxic and normoxic 
conditions. Statistical significance of p value is related to control (normoxia), at least of three independent 
experiments, *p<0.05; **p<0.01; ****p<0.0001. 
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4.3.2. Increased radiotherapy response dependent of histone lysine demethylases 
activity inhibition in esophageal squamous cell carcinoma 
In previous results (4.2.2 section), hypoxia and CoCl2 condition displayed a 
radioresistant phenotype. Thus, we investigated how the main hypoxic-dependent epigenetic 
enzymes JmjC-KDMs influenced the RT response when they are inhibited in the presence of 
IOX1.  
Figure. 27 Effect of IOX1 on cell viability of ESCC cell lines. Representative graphs of MTT performance with 0 
to 50 μM IOX1 range. For each cell line, drug effect was evaluated during 24h, 48h and 7 days. Three independent 
experiments was performed.  
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A decreased survival was found for the cell lines treated with 20 μM IOX1 at CoCl2 and 
hypoxia conditions (Figure. 28A). Overall, IOX1 treatment decreased D0 value in all the cells, 
however, it is only reached statistical significance Kyse 30 cell line (p<0.0001). Moreover, Dq, 
quasi-thereshould dose, decreases with IOX1 treatment compared with respective control 
condition (Figure. 28B). 
Additionally, the extent of sensitization [sensitize enhancement ratio (SER)], which 
evaluated drug efficacy, was also assessed. Then, Kyse 30 demonstrated the highest 
sensitization ratio, with a value of SER of 3.89 in hypoxia condition. Similarly, SF2 parameter 
was estimated, being considerably lower with IOX1treatment compared to respective hypoxia 
and CoCl2 control conditions (Figure. 28B). 
 
Figure. 28 Effect of IOX1 drug treatment on cell survival after radiotherapy. A, Cell survival fraction analysis 
after a range of IR [0; 8 Gy] in esophageal squamous cell carcinoma cell lines treated with histone lysine 
demethylase inhibitor, IOX1under hypoxic conditions. B, Summary table detailing statistical parameters such as D0, 
Dq, n, SF2 (survival fraction at 2Gy) and SER (sensitizer enhancement ratio) for all tested conditions. C+I, CoCl2 + 
IOX1; H+I, Hypoxia + IOX1; n.a, not available. Abbreviations: PE, plating efficiency; S(D), survival dependent of 
dose; SHMT, single-hit multi target. 
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To confirm the effect of IOX1 in JmjC-KDMs activity inhibition, the protein levels of 
respective histone markers were assessed. Then, H3K9me3 and H3K27me3 showed a 
tendency to increase in the presence of 20 μM IOX1, comparing to hypoxic conditions (CoCl2 
and hypoxia) in all cell lines studied (Figure. 29). 
  
 
 
4.3.3. Epigenetic modulation by histone demethylases inhibition 
4.3.3.1. Effect of inhibitory action of IOX1 on histone lysine demethylases activity 
As reported previously, for the 20 μM concentration, the H3K9me3 and H3K27me3 
increased with 50 μM IOX1, assessed by WB (Figure. 30). 
Figure. 29 Effect of 20 μM IOX1 on histone markers status. Evaluation of histone lysine demethylase activity 
through histone increment assessment. Assessment of H3K9me3 and H3K27me3 expression at normoxia, CoCl2 
and hypoxia, as well as with 20 μM IOX1. Optical density quantification was performed at hypoxic conditions (CoCl2 
and hypoxia) with normoxia [*] and IOX1 with hypoxia and CoCl2 conditions [**]. 
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Moreover, the effect of IOX1 in JmjC-KDMs and also H3K9me3 and H3K27me3 
expression were assessed by IF co-localization. In the all ESCC cell lines treated with IOX1 
inhibitor, KDM3A, KDM6B and KDM4C (green fluorescence) protein decreased, whereas 
histone markers (red fluorescence) increased compared with CoCl2 and hypoxia conditions 
Figure. 31 (and supplementary Figures 6-8 (Appendix III)). 
 
 
Figure. 30 Effect of 50 μM IOX1 on histone markers status through Western blot analysis. Assessment of 
H3K9me3 and H3K27me3  protein status for tested conditions, including normoxia, CoCl2, hypoxia, as well as 50 
μM IOX1. Optical density quantification was performed at hypoxic conditions (CoCl2 and hypoxia) with normoxia [*] 
and IOX1 with hypoxia and CoCl2 conditions [**]. 
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4.3.3.2. Histone lysine demethylases activity inhibition promotes an increased DNA damage 
after radiotherapy in hypoxic cells  
Since DNA damage decreased under hypoxic conditions, as demonstrated in 4.2.4.1 
section, we investigated how damage repair depends on KDMs activity. Indeed, higher γ-H2AX 
levels were found in the 3 ESCC cell lines after IOX1 treatment at later times (2h and 4h) after 
RT (Figure. 32A) when compared to cells exposed to CoCl2 and hypoxia, respectively. 
IOX1 inhibitor significantly increased the DNA % fragmentation at hypoxia condition for 
OE-21 cell line in all time points studied (Figure. 32B, b2), as well as for Kyse 30 cell line at 
0h and 30min after 2 Gy radiation (Figure. 32B, b1), whereas no effect was observed for Kyse 
410 cell line (Figure. 32B, b3). In the presence of 50 µM CoCl2, no differences were observed 
in the DNA % fragmentation for any of the ESCC cell lines studied (Figure. 32B). Nonetheless, 
OE-21 cell lines showed a significant increase on DNA % fragmentation when treated with 
IOX1 inhibitor.  
 
Figure. 31 Effect of IOX1 treatment on KDMs activity and respective histone markers status. Representative 
merged pictures of KDM3A, KDM6B and KDM4C and respective histone markers, H3K9me3 and H3K27me3 for all 
ESC cell lines. Histone lysine demethylases were stained with green fluorescence and histone markers with red 
fluorescence.  
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Figure. 32 Effect of histone demethylases inhibition on DNA damage. A, Immunofluorescence with γ-H2AX 
antibody at 30 min, 2h and 4h after 2 Gy radiotherapy  comparing IOX1 with hypoxic conditions (control). B, DNA 
damage extent evaluation through comet assay with IOX1 at 0h, 30 min and 2h after ionizing radiation normalized to 
control without radiation. Representation of microscopic images and respective statistical graphs, ns – non significance; 
** p<0.01; ***p<0.001; ****p<0.0001.  
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4.3.3.3. Cell cycle checkpoints deregulation dependent of histone lysine demethylases, Jumonji 
c domain family activity 
Cell cycle checkpoints were also assessed after IOX1 treatment. Specifically, TP53 and 
RAD9A transcriptional levels were found to be decreased at 30min and 24h after IR with 50 µM 
IOX1 compared to hypoxia control condition (Figure. 33). Similarly, in the presence of 50 µM 
CoCl2 condition for both time points, 50µM IOX1 significantly decreased TP53 and RAD9A 
(Figure. 33), with exception of Kyse 30 at 30min (Figure. 33A). Conversely, transcriptional 
CDKN1A levels significantly increased with IOX1 at 30min and 24h after RT in hypoxia and 
CoCl2 condition, except for OE-21 at 24h and also Kyse 30 and OE-21 at 30min for CoCl2 
condition (Figure. 33). MDM2 expression increased in hypoxia at 30 min and 24h after RT, 
excepting Kyse 30 and Kyse 410 at 30min (Figure. 33). In opposition, CoCl2 condition at 24h 
after RT, MDM2 decreased expression was observed (Figure. 33B).  
Figure. 33 Effect of IOX1 inhibitor on cell cycle deregulation. Representative graphs of TP53, CDKN1A, MDM2 
and RAD9 gene expression at 30 minutes and 24 hours after ionizing radiation (2 Gy) compared to hypoxia 
conditions, ns – non significance; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
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4.3.3.4. Decrease of cell aggressiveness features of esophageal squamous cell carcinoma 
cells in response to histone lysine demethylase inhibitory drug treatment 
Unlike previously observed, where hypoxia and HIF-1α in the presence of 2 Gy IR 
promotes an increases in cell migration, KDM activity inhibition with IOX1 reverts this effect, 
leading to a significantly decrease on cell migration at 24h in ESCC cell lines used (Figure. 
34).  
 
Figure. 34 Inhibitory effect of IOX1 on cell migration of ESCC cell lines under CoCl2 and hypoxia conditions.  
Representative images of wound healing assay and respective statistical graphs characterizing the percentage of 
cell migration with 24 hours of treatment, at least of three independent experiments; *** p<0.001; **** p<0.0001. 
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Moreover, IOX1 treatment increased the number of apoptotic cells with 2 Gy IR therapy 
in CoCl2 and hypoxia condition (Figure. 35). 
  
 
 
 
 
 
 
 
  
Figure. 35 Effect of IOX1 treatment in cell apoptosis induction. Percentage of cell apoptosis with 50 μM IOX1 
condition compared to respective control (IOX1 vs CoCl2 and IOX1 vs hypoxia) in esophageal squamous cell 
carcinoma cell lines;  media±SEM at least of three independent experiments. * p<0.05, ** p<0.01, *** p<0.001. 
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ESCC has a high global incidence with poor prognosis and a low overall survival rates. 
Thus, new therapeutic approaches to improve the prognosis of these patients is crucial [3, 114]. 
Gold standard therapy for advanced ESCC includes chemo- and RT followed by surgical 
resection. In spite of therapeutic advances, the outcome and disease-free survival percentage 
remains poor [115].  
Hypoxic regions are a common feature in most solid tumors and also constitute a major 
cause of RT resistance, being associated with increased cell proliferation, migration, invasion, 
cell cycle deregulation, metabolic instability and overall tumor progression [56, 60, 63, 64, 116, 
117]. Currently, the transcription factor HIF-1α, is acknowledged a major mediator of hypoxia 
adaptation in tumor cells, being involved in gene transcription regulation by HRE. Several 
studies have proposed this transcription factor as a novel therapeutic target [118].  
In the last few years’ remarkable new findings emerged in epigenetics cancer therapy. 
Epigenetics abnormalities induce cancer progression and phenotypes remodeling [97]. 
Therefore, knowledge of chromatin dynamic changes, particularly, in HIF-1α downstream 
signaling pathways regulation, might add relevant information on tumor biology [105, 119, 120]. 
Indeed, some epigenetic enzymes, such as JmjC-KDMs family have already been described 
on the literature as being upregulated in hypoxia conditions [81, 121]. Additionally, 
KDM3A/JMJD1A, KDM4C/JMJD2C and KDM6B/JMJD3 were reported to be intrinsically 
related with hypoxic microenvironment interacting with HIF-1α [81]. 
In the present study, we intended to understand the impact of hypoxia 
microenvironment on RT response in ESCC, through the dynamic interaction between HIF-1α 
and JmjC-KDMs. 
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5.1 Histone lysine demethylases, Jumonji c domain family upregulation in 
esophageal squamous cell carcinoma seem to be associated with hypoxic 
regions  
JmjC-KDMs are thoroughly reviewed on the literature as cancer development 
mediators. These alterations tend to imply both active or repressed gene transcription and plays 
a key role on chromatin regulation processes [75]. Moreover, we also focused our attention on 
specific KDMs related to ESCC poor prognosis.  
Three major histone demethylases of JmjC superfamily containing KDMs, namely 
KDM3A, KDM6B and KDM4C, have been previously reported to be important in cancer 
development, as possible therapeutic targets. Accordingly, we have found that KDM3A and 
KDM6B were significantly upregulated in human ESCC compared to normal esophageal 
tissues, with significant nucleic overexpression, showing to be important for ESCC 
development. In fact, KDM3A, although no data is available for EC, it has been identified as a 
novel therapeutic target candidate, strongly correlated with hypoxia-inducible pathways, with 
prognostic and tumor development impact in several cancer models, including colorectal 
cancer [122], hepatocellular carcinoma [123] and renal cell carcinoma [124]. Moreover, this 
enzyme plays an important role on DNA damage repair and in cell cycle regulation G1/S 
transition phase, being implicated in cell survival and tumor growth. Similar to KDM4C, this 
demethylase catalyzes H3K9me3 modulation [125]. Additionally KDM6B, a specific target 
regulator of H3K27 methylation, has a comparable effect on cancer pathogenesis and is 
deregulated in EC, as well as in many other primary cancers [126].  
Furthermore, since EC, particularly squamous subtype, is characterized by the 
presence of hypoxic regions [127, 128], we also assessed HIF-1α protein expression in the 
same series to characterize the hypoxic status of this samples, once it is a critical marker of 
aggressiveness [129]. IHC analysis demonstrated a strong presence of this hypoxia mediator 
in 40% of ESCC cases.  
Although, JmjC-KDMs regulation in hypoxic cellular context is not fully understood, , it 
has been described that these enzymes are increased in the presence of HIF-1α, thus being 
sensitive to oxygen status [81]. Some KDMs, including, KDM3A/JMJD1A, KDM6B/JMJD3 and 
KDM4C/JMJD2C, directly bind to HIF-1α, acting in an oxygen-sensitive way. Indeed, specific 
HIF-1α binding sites to JmjC-KDMs, through HREs [130], and increased expression of these 
enzymes were already demonstrated in hypoxic conditions [87, 131] [80, 88, 132]. In fact, in 
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our ESCC cohort, KDMs expression, particularly KDM3A, significantly associated with HIF-1α 
expression, and trend was found for KDM6B. Moreover, our in vitro results indicate that both 
low oxygen levels and HIF-1α chemical induction, upregulate KDM3A, KDM4C and KDM6B 
transcription and protein levels. Importantly, decreased H3K9me3 and H3K27me3 expression 
levels were also found. Additionally, HIF-1α protein was found bind specifically to genomic 
regions of KDM3A, KDM6B and KDM4C. Thus, our findings suggesting that JmjC-KDMs are 
regulated by HIF-1α protein, highlighting the importance of the hypoxic microenvironment 
dynamics in epigenetic machinery function. Furthermore, our results implicates KDM3A in 
ESCC tumorigenesis, as well as hypoxia-associated phenotype, since this KDM has a higher 
prevalence in ESCC tissues (68%, [47/69]), as well as an increased expression in hypoxic 
microenvironment, when compared to other studied KDMs. 
 
5.2 Histone lysine demethylases, Jumonji c domain family upregulation in 
hypoxia modified the outcome of radiotherapy response in esophageal 
squamous cell carcinoma  
Besides the aggressive hypoxic features in solid tumors, low oxygen levels were 
associated with RT response, increasing the radioresistance and consequently higher overall 
survival rates [63, 133]. Considering the R’s of radiobiology, oxygen plays an important role on 
RT response, clearly demonstrated by clonogenic experiments [116, 134]. Accordingly, in our 
hands, under hypoxia conditions, a significant cell survival increase was found for most of the 
cell lines. Thus, our results with CoCl2 also support the fact that HIF-1α is involved in acquired 
radioresistance. The absence of a significant effect of hypoxia and CoCl2 on cell survival after 
RT treatment for Kyse 410 cell line indicates, once again, the involvement of HIF-1α in RT 
response, since this cell expresses HIF-1α at normal oxygen levels. 
Although many therapeutic strategies have already been proposed to revert tumor 
hypoxia, such as using hypoxic radiosensitizers, this topic remains controversial and the tumor 
can escape and acquire dynamic heterogeneous resistant properties [135, 136]. Thus finding 
targeted therapies that might be regulated by HIF-1α transactivation, including epigenetic 
modulation, is of utmost importance. Several authors have proposed specific JmjC-KDMs as 
complementary targeted therapies for histone methylation on cancer models, resulting in 
cancer patients’ improved overall survival [107, 137-141]. Rath et al. demonstrated that 
KDM6B/UTX inhibition has antitumor survival properties in lung and breast cancers, which 
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improved RT response, enhancing H3K27me3 [137]. However, no correlation was found 
between these radioresistant properties and hypoxia. Additionally, KDM3A was identified as a 
novel prognostic marker in colorectal cancer, being involved in RT resistance and hypoxia 
[122]. Similarly, KDM4C expression was also shown to associate with tumor initiation and 
progression and decreased patients’ overall survival [142, 143]. Both KDM3A and KDM4C were 
implicated in H3K9me3 specific regulation [79, 143]. Thus, KDMs overexpression might, 
indeed, alter several regulatory events in carcinogenesis [75].  
Further, knowing that cell cycle and DNA damage repair plays a key role in RT response 
[55, 144], we assessed whether hypoxia and HIF-1α stabilization together with KDMs 
overexpression, impact cell cycle checkpoints and DNA damage repair to confer 
radioresistance. Here in, we have used γ-H2AX as surrogate marker, since its phosphorylation 
in the presence of DNA DSB, initiates several repair mechanisms through activation of DNA 
damage-response factors after IR and hypoxic-dependent pathways activation [145-148]. In 
fact, in our in vitro assays, γ-H2AX dynamic accumulation begins before normoxia, indicating 
a more active response for DNA DBS repair. This observation was corroborated by the higher 
DNA damage observed in normoxic than in hypoxic conditions, particularly in OE-21 cell line, 
whom HIF-1α induction was more evident.  
Consequently, under hypoxia decreased apoptotic levels and increased cell migration 
were found in comparison to normoxia. Thus, hypoxic environment through HIF-1α pathway 
increased ESCC aggressiveness cells, which might support the increased radioresistance. 
Overall these findings are in accordance with previous reports available [149]. Further, cell 
cycle deregulation under hypoxia was also corroborated through G1-S and G2-M transition by 
TP53, CDKN1A, MDM2 and RAD9A checkpoints deregulation. Accordingly, TP53 tumor 
suppressor gene, an apoptotic inducer through activation of proapoptotic genes, such as Bcl-2 
family, coupled with CDKN1A were downregulated [150, 151]. Thus, our study demonstrates 
that in hypoxic conditions, p53 and CDKN1A genes downregulation might be due to DNA 
damage repair activation inducted after IR. Conversely, no consistent results were observed 
for MDM2, a tightly regulator of TP53, acting antagonistically, is responsible for the 
ubiquitination of TP53 [152], which may be explained by eventual TP53 mutations. Likewise, 
ESCC cell lines, immediately after radiation induced DNA damage displayed RAD9A 
downregulation in hypoxic conditions compared to normoxia, resulting in increased cell 
survival, as observed with RT treatment through increased cellular proliferation. This tumor 
suppressor have been also shown to promote cell apoptosis by interact with BCL-2 family [153]. 
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Overall, we were able to demonstrate that JmjC-KDMs –derived HIF-1α modulation is 
relevant for ESCC patients prognosis because its deregulation increased aggressiveness and 
cell survival, as well as RT resistance, through cell cycle deregulation, DNA damage repair and 
cell migration. 
 
5.3 Improvement of radiosensitivity in hypoxic esophageal squamous cell 
carcinoma cells through histone lysine demethylases, Jumonji c domain 
family activity inhibition 
Knowing that hypoxia confers RT resistance and that epigenetic modulation, by JmjC-
KDMs family, we investigated how histone demethylase inhibition might affect RT response in 
ESCC. A novel global KDM inhibitor, IOX1 [154], was used to reverse the tumorigenic and 
aggressive effects induced by KDMs upregulation in hypoxia. Indeed, our results showed that 
although Kyse 30 is the most sensitive cell line, other cell lines also showed a tendency, yet 
not statistically significant to increase radiosensitivity. Remarkably, all cell lines showed 
increased SER for this chemical inhibitor. Moreover, Dq was higher when the tumor was less 
radiosensitive [155]. Accordingly, after JmjC-KDMs inhibition lower Dq values in all ESCC cell 
lines were observed. Moreover, the value of SF2 was also lower with IOX1, indicating higher 
death percentage. Our results follow previous studies that demonstrated that IOX1 associates 
with decreased cell proliferation and survival [156, 157].   
Furthermore, phenotypic features, including DNA damage repair, migration, apoptosis 
and cell cycle deregulation, showed that JmjC-KDMs inhibition promotes decreased cellular 
aggressiveness. Particularly, DNA damage after IR treatment (2 Gy) was increased as shown 
by comet assay and γ-H2AX analysis in the all tested cell lines, but none Kyse 410. Accordingly, 
decreased migration capacity and increased apoptosis percentage was also observed in these 
cells. Nonetheless, regarding cell cycle checkpoints analysis, only increased CDKN1A 
expression was found after KDMs inhibitor treatment, which might explain the apoptotic 
induction observed and consequently increased radiosensitivity. On the other hand, possible 
compensatory mechanisms, due to increased MDM2 expression might justify TP53 and 
RAD9A decreased expression.  
Hence our results support the role of JmjC-KDMs in mediating ESCC development and 
aggressiveness, and further sustains their value as putative novel candidates to targeted 
therapy. 
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The understanding of hypoxic-dependent pathways subjacent to epigenetic regulation, 
has been an emerging topic in oncology with critical implications on new therapeutic 
approaches. Moreover, specific JmjC-KDMs have been suggested to play a role in HIF-1α 
regulation and subsequent gene transcription modulation.  
Overall, it is known that EC patients show shorted overall survival rates, and therefore 
it is of major importance to improve the therapeutic efficacy in these patients. Specifically, due 
to tumor’s location, RT is a standard treatment approach in which several forms of resistance 
may develop like hypoxia. In this dissertation we demonstrated the role of JmjC-KDM-HIF-1α 
interactions in IR response of ESCC cell models. Moreover, overexpression of the tested 
histone demethylases was associated with EC aggressiveness and limited RT response. 
Consequently, our results supports the role of epigenetic modulation on RT under hypoxic 
microenvironment, highlighting JmjC-KDMs as a putative therapeutic target on ESCC cancer 
patient’s survival improvement.  
Importantly, to further support our experimental findings we intend to extend this study 
to other EC subtypes – EAC, corroborate in vitro results with in vivo cancer models and also 
test JmjC-KDMs inhibitors combined with RT as new therapeutic approach for EC patients 
[158].   
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Epidemiological studies on obesity and/or central adiposity in association with esophageal adenocarcinoma risk, 
and GERD, and BE. Abbreviations: BE, Barrett’s esophagus; CI, Confidence interval; GERD, gastroesophageal 
reflux disease; NS, non-significant; OR, Odds ratio. a number of the studies. 
 
Appendix I 
 
Supplementary Table. 1 
  
Esophageal Adenocarcinoma
Reference Design Study Parameters Sample Size OR CI 95%
(Kubo and Corley 2006) Meta-analysis
results
Normal Weight
1 (referent)
Overweight + obese 11a 1.7 [1.6;1.9]
Overweight 6a 1.9 [1.5;2.4]
obese 6a 2.4 [2.0;2.8]
(Brown, Swanson et al. 1995) Case-control BMI <23.1 Kg/m2 24 1 (referent)
BMI 23.1-25.0 kg/m2 31 1.1 [0.6;2.1] NS
BMI 25.1-26.6 kg/m2 27 1.2 [0.6;2.3] NS
BMI >26.6 kg/m2 79 3.1 [1.8;5.3]
(Chow, Blot et al. 1998) Case-control I-low: males <23.12; 
females <21.95
45 1 (referent)
II- males: 23.12-25.08; 
females: 21.95-24.12
63 1.3 [0.8;2.2] NS
III-males: 25.09-27.31; 
females: 24.13-27.43
85 2.0 [1.3;3.3]
IV- High: males =27.32; 
females =27.44
99 2.9 [1.8;4.7]
(Engel, Chow et al. 2003) Case-control BMI 17.6-22.9 kg/m2 48 1 (referent)
BMI 23.0-24.9 kg/m2 56 1.3 [0.8;2.2] NS
BMI 25.0-26.9 kg/m2 77 2.0 [1.2;3.2]
BMI 27.0-43.3 kg/m2 111 2.7 [1.7;4.4]
(Hampel, Abraham et al. 2005) Meta-analysis 
results
Total = 8a
BMI 25-30 kg/m2 1.52 [1.15;2.01]
BMI > 30 Kg/m2 2.78 [1.85;4.16]
(Singh, Sharma et. Al, 2013) Meta-analysis
results
Central adiposity Total = 6a 2.51 [1.54;4.06]
Gastroesophageal Reflux Disease
(Hampel, Abraham et al. 2005) Meta-analysis results Total = 8a
BMI 25-30 kg/m2 1.43 [1.16;1.77]
BMI > 30 Kg/m2 1.94 [1.47;2.57]
(Nilsson, Johnsen et al. 2003) Case-control BMI units:
0.5-1.5 399 1.2 [1.0;1.4] NS
>1.5-3.5 805 1.6 [1.4;1.8]
>3.5 636 2.7 [2.3;3.2]
Barrett’s Esophagus
(El-Serag, Kvapil et al. 2005) Case-control BMI 25-30 kg/m2 1.69 [0.67;4.23] NS
BMI > 30 Kg/m2 4.00 [1.44;11.01]
(Jacobson, Chan et al. 2009) Prospective Cohort 
Study in Nurses
BMI: 20-24.9 Kg/m2 1 (Referent)
BMI:25-29.9 Kg/m2 34 0.92 [0.66;1.27] NS
BMI ?30 Kg/m2 13 1.52 [1.02;2.28]
BMI ? 20 Kg/m2 0.92 [0.65;1.31] NS
(Edelstein, Farrow et al. 2007) Case-control BMI ?25 Kg/m2 37 1 (referent)
BMI: 25-29.99 
Kg/m2
75 1.6 [0.9;2.8] NS
BMI = 30 Kg/m2 79 2.6 [1.5;4.4]
(Singh, Sharma et. Al, 2013) Meta-Analysis results Central adiposity 17a 1.98 [1.52;2.57]
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Supplementary Table. 2 
 
Reference Design Study Parameters Sample Size OR CI 95%
(Rugge, Zaninotto et al. 2012) Prospective 
Cohort *
Absent 1 (referent)
Low-Grade intraepithelial 
neoplasia (LG-IEN)
3.74b [1.22;11.43]
Normal 1 (referent)
Appearance of lesion 
(nodulary or ulceration)
7.6b [2.63;21.98]
Longer BE length 1.16b [1.03;1.30]
(Hvid-Jensen, Pedersen et al. 
2011)
Cohort Patients with Barrett’s 
Esophagus
11,028 11.3b [8.8;14.4]
Epidemiological studies on BE in association with esophageal adenocarcinoma risk. Abbreviations: BE, Barrett’s 
esophagus; CI, Confidence interval; OR, odds ratio. b risk ratio (RR); * study about BE for progression  to high grade 
intraepithelial neoplasia or  esophageal adenocarcinoma. 
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Supplementary Table. 3 
Epidemiological studies on GERD in association with esophageal adenocarcinoma risk. Abbreviations: CI, 
confidence interval; GERD, gastroesophageal reflux disease; NS, non-significant; OR, odds ratio. 
  
 
 
Reference Design Study Parameters Sample Size 
(cases)
OR CI 95%
(Lagergren, Bergstrom et al. 1999) Case-control Heartburn, regurgitation, or 
both at least once a week:
No 76 1(referent)
Yes 113 7.7 [5.3;11.4]
Heartburn, regurgitation, or 
both at night at least once a 
week:
No 88 1 (referent)
Yes 101 10.8 [7.0;16.7]
Frequency of Reflux 
Symptoms:
No symptoms 76 1 (referent)
1 time/week 37 5.1 [2.8;9.4]
2 to 3 times/week 35 6.3 [3.8;10.3]
>3 times/week 41 16.7 [8.7;28.3]
Duration of Reflux 
Symptoms:
No symptoms 76 1 (referent)
<12 years 31 7.5 [4.2;13.5]
12-20 years 42 5.2 [3.1;8.6]
>20 years 40 16.4 [8.3;28.4]
(Engel, Chow et al. 2003) Case-control Frequency of 
gastroesophageal reflux 
disease symptoms:
Never 1 (referent)
1-2 times/year 0.5 [0.2;1.0]NS
3-12 times/year 1.2 [0.7;2.0]NS
13-104 times/year 2.0 [1.2;3.1]
105-364 times/year 3.2 [1.9;5.7]
= 365 times/year 4.9 [2.9;8.1]
Any Gastroesophageal reflux 
disease symptoms
2.0 [1.4;2.7]
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Supplementary Table. 4 
Epidemiological studies on smoking in association with esophageal cancer risk. Abbreviations: AC, 
adenocarcinoma; CI, confidence interval; OR, odds ratio; SCC, squamous cell carcinoma. 
 
 
 
 
 
Esophageal AC
Reference Design study Parameters Sample Size (cases) OR CI 95%
(Engel, Chow et al. 2003) Case-control Never 63 1 (referent)
Former 144 1.9 [1.3;2.8]
Current 86 2.3 [1.5;3.6]
(Cook, Kamangar et al. 2010) Case-control Ever-cigarette
smoking
1098 1.96 [1.64;2.34]
(Wu, Wan et al. 2001) Case-control Total=222
Never 1 (referent)
Former 1.52 [1.0;2.2]
Current 2.80 [1.8;4.3]
(Lagergren, Bergstrom et al. 2000) Case-control Never 57 1 (referent)
Former 89 1.9 [1.2;2.9]
Current 43 1.6 [0.9;2.7]
Esophageal SCC
(Brown, Hoover et al. 2001) Case-control Cigarette-smoking
white men
119 3.1 [1.2;8.5]
Cigarette-smoking
black men
228 2.5 [1.1;5.6]
(Engel, Chow et al. 2003) Case-control Never smokers 22 1 (referent)
Former smokers 91 2.1 [1.2;3.8]
Current smokers 108 3.5 [1.9;6.5]
(Pandeya, Olsen et al. 2013) Case-control Never smokers 77 1 (referent)
Former smokers 141 2.3 [1.6;3.3]
Current smokers 93 4.9 [3.2;7.4]
(Lagergren, Bergstrom et al. 2000) Case-control Never smokers 22 1 (referent)
Former smokers 44 2.5 [1.4;4.7]
Current smokers 101 9.3 [5.1;17.0]
(Liu, Wang et al. 2017) Case-control Never smokers 360 1 (referent)
Ever smokers 582 2.81 [2.12;3.73]
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Supplementary Table. 5 
Epidemiological studies on alcohol consumption in association with esophageal cancer. Abbreviations: AC, 
adenocarcinoma; CI, confidence interval; NS, non-significant; OR, odds ratio; SCC, squamous cell carcinoma 
  
Esophageal SCC
Reference Design Study Parameters Sample Size OR CI 95%
(Engel, Chow et al. 2003) Case-control Total No. 221
Never 1 (referent)
<5 drinks/week 1.3 [0.6;3.0]NS
5-11 drinks/week 2.5 [1.1;5.6]
12-30 drinks/week 4.7 [2.2;9.7]
>30 drinks/week 9.4 [4.6;19.2]
Any alcohol consumption 4.2 [2.2;8.1]
(Brown, Hoover et al. 2001) Case-control Alcohol Intake white man 119 6.8 [3.5;13.4]
Alcohol Intake Black man 228 8.3 [4.3;15.8]
(Pandeya, Olsen et al. 2013) Case-control Total No. 305
= 17 drinks/week 1 (referent)
> 17 drinks/week 3.3 [2.4;4.7]
(Lagergren, Bergstrom et al. 2000) Case-control Never consumer 16 1 (referent)
Ever consumer 651 2.0 [1.1;3.5]
(Liu, Wang et al. 2017) Case-control Never Drinkers 333 1 (referent)
Ever Drinkers 609 1.95 [1.48;2.55]
>443.8 g Ethanol/week 190 7.16 [4.61;11.13]
Esophageal AC
(Wu, Wan et al. 2001) Case-control Alcohol use Total No.222
Never 1 (referent)
Former 0.74 [0.5;1.2] NS
Current 0.70 [0.5;1.1] NS
(Lagergren, Bergstrom et al. 2000) Case-control Never consumer 132 1 (referent)
Ever consumer 688 0.5 [0.3;0.9]
Grams of ethanol per week:
1-15 221 0.6 [0.4;1.1] NS
16-70 289 0.4 [0.2;0.7]
>70 178 0.6
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Supplementary Table. 6 
Epidemiological studies on consumption of fruits and vegetables in association with esophageal squamous cell 
carcinoma risk. Abbreviations: CI, confidence interval; NS, non-significant; OR, odds ratio. * HR, hazard ratio.  
 
  
Reference Design Study Parameters Sample Size OR CI 95%
(Yamaji, Inoue et al. 2008) Survival Analysis 120-209 g/day 55 1 (referent)
282-362 g/day 40 0.65* [0.43;0.98]
466-672 g/day 21 0.30* [0.18;0.50]
(Liu, Wang et al. 2017) Case-control Quartile 1 317 1 (referent)
Quartile 2 221 0.80 [0.61;1.05] NS
Quartile 3 205 0.74 [0.56;0.98]
Quartile 4 199 0.70 [0.53;0.92]
(Freedman, Park et al. 2007) Cohort (98,161) ˜ 1.5 servings/day 40 1 (referent)
˜ 2.4 servings/day 26 0.93 [0.56;1.55] NS
˜ 3.2 servings/day 18 0.74 [0.41;1.34] NS
˜4.1 servings/day 10 0.46 [0.22;0.96]
˜5.8 servings/day 9 0.44 [0.20;0.96]
<2 times/day 1.4 [1.0;1.9] NS
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Appendix II 
 
 
Supplementary Table.1 
 
 
SupplementaryTable. 2  
qRT-PCR primers optimized conditions and details. Forward and reverse sequences; annealing temperature; primer 
volume 
 
 
 
Summary table of the antibodies used in IHC performance. Abbreviations: EDTA, ethylenediamine 
tetraacetic acid; IHC, immunohistochemistry;   
Primary Antibody Company IHC Dilution Antigen Retrieval Buffer Positive Control
HIF-1a Cell Signaling, 36169S 1:500
1mM EDTA
pH=8
Clear Cell Renal Cell 
Carcinoma
KDM3A Abcam, ab91252 1:150
1mM EDTA
pH=8
Urothelial carcinoma
KDM6B Abcam, ab38113 1:250
1mM EDTA
pH=8 Colorectal Carcinoma
Gene Forward Sequence (5 -3 ) Reverse Sequence (5 -3 )
T Annealing (ºC)/Primer 
Volume (µL)
ß-Gus CACTGAAGAGTACCAGAAAAGTC TCTCTGCCGAGTGAAGATCC 60ºC; 0.5 µL
CDKN1A(p21) TGCCGAAGTCAGTTCCTTGT GTTCTGACATGGCGCCTCC 60ºC;0.5 µL
HIF-1a CAAGAACCTACTGCTAATGCCACC GTATGTGGGTAGGAGATGGAGATG 64ºC;0.5 µL
KDM3A  GTGGGGATTGATTTGGACAC TCTTCATCCGGTAGCAGTCC 62ºC;0.5 µL
KDM6B GGGTGATGATTGGCTTTCTG TGATAAGAGTGCCCGCTACC 62ºC;0.5 µL
KDM4C CTTGAAAGACTAGCTCAAGG CAGTTGAAACCATGATTAAA 60ºC; 0.5 µL
MDM2 AGGAGATTTGTTTGGCGTGC TGAGTCCGATGATTCCTCCTG 60ºC;0.3 µL
RAD9 GTGAAGGTGCTCGGCAAGG CCAAGGGTTCCAGGTAGAGC 60ºC;0.5 µL
TP53 CGCTTCGAGATGTTCCGAGA CTTCAGGTGGCTGGAGTGAG 60ºC;0.5 µL
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Supplementary Table. 3 
Primary antibodies used in western blot and immunofluorescence assays. Description of respective optimized 
dilutions and secondary antibodies 
 
Supplementary Table. 4 
 
 
Supplementary Table. 5 
Specific details of primary antibodies used for immunoprecipitation assay. 
 
Cells Seeded
Cell line Normoxia CoCl2 Hypoxia CoCl2+ IOX1 Hypoxia + IOX1
Kyse 30 1000 N.A 1000 N.A 5000
OE-21 1300 2300 1300 5000 5000
Kyse 410 2500 3000 2500 5000 5000
Cells concentration on colony formation assay in 6-well plates for each cell line condition. N.A, not available. 
Primary Antibody Company
ChIP dilution
/10 million of cells
HIF-1a Abcam, ab1 5 µL
Normal IgG Mouse Millipore, 12-371 1 µL
RNA Polymerase II Millipore, 05-623 1 µL
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Supplementary Table. 6 
ChIP qRT-PCR primers specific conditions including detailed information about forward and reverse sequence, 
distance from transcriptional starting site (TSS), annealing temperature and primer volume. 
 
 
 
Gene Primer Forward Sequence(5 -3 ) Reverse Sequence(5 -3 )
Distance from 
TSS
Tºanneling (ºC)/ 
Primer Volume (µL)
KDM3A
A TGGGAGGCATGAGTTCTTCT TGTGTGCTCTGGACCTGAAG 689 bp 62ºC; 0.3 µL
B TCACCTTAGGATAGGCCATGTT TGGTAGCCAAATGAAAGCAG 1242 bp 60ºC; 0.3 µL
KDM6B
A TAGGACTCAGGCTGGCTTGT AAACCCGTGATCCCTCTTCT 723 bp 60ºC; 0.3 µL
B TCTTGGCCTTGGACTTATGC TATCCTGTTTCCCCATCACC 1115 bp 60ºC; 0.3 µL
C AGTGTCATCAGCACAGCCACAG CACTTGGGGTCCCAATCTAA 1367 bp 60ºC; 0.3 µL
KDM4C
A CTGTCACCTAGTGCGGAACA ATGGTTAGGGCAGTGTCTGG 98 bp 60ºC; 0.3 µL
B TCTTCGCCTATTCGGGATCT GAGCCTCGGAATGTACTGGA 450 bp 60ºC; 0.3 µL
C CACCCCAGTGAGAAACGAGT TGGGCATATCTTCACACCAG 1300 bp 60ºC; 0.3 µL
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Appendix III 
 
 
Supplementary Figure. 1 Assessment of HIF-1α protein expression after CoCl2 treatment. Western blot 
images representing protein extraction at three time points (24H, 72H and 144H) after a single addition of HIF-1α 
chemical inductor (CoCl2), comparing to the normoxia condition. N, normoxia. 
 
Supplementary Figure. 2 Assessment of specific JmjC-KDMs basal levels. Representative graph of Jumonji C 
domain histone lysine demethylases (JmjC-KDMs) (KDM3A, KDM6B and KDM4C) transcriptional levels for 
esophageal squamous cell carcinoma cell lines through qRT-PCR.  
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Supplementary Figure. 3 KDM3A overexpression under hypoxic conditions. KDM3A protein expression under 
hypoxia and CoCl2 conditions compared to normoxia through immunofluorescence. The KDM3A protein was stained 
with green fluorescence and histone marker (H3K9me3) with red fluorescence. (200x magnification). DAPI, 4',6-
Diamidine-2'-phenylindole 
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Supplementary Figure. 4 KDM6B overexpression under hypoxic conditions. KDM6B protein expression under 
hypoxia and CoCl2 conditions compared to normoxia through immunofluorescence. The KDM6B protein was stained 
with green fluorescence and histone marker (H3K27me3) with red fluorescence. (200x magnification). DAPI, 4',6-
Diamidine-2'-phenylindole 
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Supplementary Figure. 5 KDM4C overexpression under hypoxic conditions. KDM4C protein expression under 
hypoxia and CoCl2 conditions compared to normoxia through immunofluorescence. The KDM4C protein was stained 
with green fluorescence and histone marker (H3K9me3) with red fluorescence. (200x magnification). DAPI, 4',6-
Diamidine-2'-phenylindole 
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Supplementary Figure. 6 Effect of IOX1 treatment on KDM3A expression in ESCC cell lines. KDM3A protein 
expression under IOX1 treatment compared to hypoxia and CoCl2 through immunofluorescence. The KDM3A protein 
was stained with green fluorescence and histone marker (H3K9me3) with red fluorescence. (200x magnification). 
DAPI, 4',6-Diamidine-2'-phenylindole 
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Supplementary Figure. 7 Effect of IOX1 treatment on KDM6B expression in ESCC cell lines. KDM6B protein 
expression under IOX1 treatment compared to hypoxia and CoCl2 through immunofluorescence. The KDM6B protein 
was stained with green fluorescence and histone marker (H3K27me3) with red fluorescence. (200x magnification). 
DAPI, 4',6-Diamidine-2'-phenylindole 
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Supplementary Figure. 8 Effect of IOX1 treatment on KDM4C expression in ESCC cell lines. KDM4C protein 
expression under IOX1 treatment compared to hypoxia and CoCl2 through immunofluorescence. The KDM4C 
protein was stained with green fluorescence and histone marker (H3K9me3) with red fluorescence. (200x 
magnification). DAPI, 4',6-Diamidine-2'-phenylindole 
